Chimeric polypeptides
By designing optimized chimeric or fusion proteins containing the active sites and adhesin domains of Arg-gingival protease or Lys-gingival protease from Porphyromonas gingivalis, the problem of lacking an effective immune response in existing technologies has been solved, achieving effective prevention and treatment of Porphyromonas gingivalis infection.
Patent Information
- Application Number
- CN202380027378.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-20
- Filing Date
- 2023-01-20
- Publication Date
- 2024-11-12
AI Technical Summary
There is a lack of effective methods in the current technology to induce a strong protective immune response to prevent or treat Porphyromonas gingivalis infection, and there is no commercially approved vaccine available.
A chimeric or fusion protein was designed, containing the active site and adhesin domain of Arg-gingival protease or Lys-gingival protease from Porphyromonas gingivalis. By combining specific amino acid sequences, the protein's solubility and stability were optimized, its aggregation tendency was reduced, and its immunogenicity was improved.
It improves the immune response to Porphyromonas gingivalis, enhances protective immunity against Porphyromonas gingivalis infection, effectively reduces or treats related symptoms, and provides a treatment option for Porphyromonas gingivalis-related diseases.
Smart Images

Figure BDA0005041071400000131 
Figure BDA0005041071400000141 
Figure BDA0005041071400000151
Abstract
Description
Technical Field
[0001] The present invention relates to chimeric polypeptides that can be used to induce an immune response to Porphyromonas gingivalis (P. gingivalis), compositions comprising the chimeric polypeptides, and uses thereof for preventing and treating P. gingivalis-associated conditions and diseases.
[0002] Related applications
[0003] This application claims priority from Australian provisional application No. AU 2022900102, the entire contents of which are hereby incorporated by reference. Background Art
[0004] When plaque accumulates around the teeth at the margins of the gums (gingival or gum), it causes inflammation of the gums (gingivitis). Chronic gingivitis can allow the periodontal pathogen Porphyromonas gingivalis (P. gingivalis) to settle in the base of the periodontal pockets, leading to chronic infection and the development of advanced disease. This advanced periodontal disease is called periodontitis and can lead to tooth loss as the immune system eliminates the infection.
[0005] Chronic periodontitis is an inflammatory disease of the supporting tissues of the teeth, leading to resorption of alveolar bone and eventual tooth loss. The disease is a major public health problem in all societies and is estimated to affect up to 30% of the adult population, with severe forms affecting 12-15%.
[0006] One-third of adults suffer from moderate to severe periodontitis. According to epidemiological surveys, periodontitis is associated with an increased risk of inflammatory diseases (including cardiovascular disease, certain cancers, premature birth, rheumatoid arthritis and dementia). Recent studies have linked chronic infection with Porphyromonas gingivalis to dementia and rheumatoid arthritis. For example, in one study, 96% of Alzheimer's disease (AD) brain samples showed the presence of Porphyromonas gingivalis. Another study showed that chronic oral infection of mice with Porphyromonas gingivalis caused brain plaques associated with human AD, and that Porphyromonas gingivalis protease can cleave amyloid precursor and tau protein to form plaques and tangles associated with AD.
[0007] Many virulence factors have been reported to contribute to the pathogenicity of P. gingivalis, including: LPS, fimbriae, hemagglutinins, hemolysins, and extracellular hydrolases (especially Arg-X and Lys-X specific proteases), also known as "P. gingivalis gingipains".
[0008] The significance of the public health problem creates a need for a vaccine that provides a strong protective response to P. gingivalis infection and methods of providing the same.
[0009] One problem is that it is unclear how to obtain a strong protective response to P. gingivalis infection given the large number of virulence factors available.
[0010] There are currently no commercially approved vaccines for preventing or reducing the incidence and / or severity of P. gingivalis infection, or for treating P. gingivalis infection and disease in a subject.
[0011] Therefore, there is a need for alternative and / or improved methods for designing and preparing P. gingivalis vaccines, as well as alternative and / or improved vaccines produced by P. gingivalis.
[0012] The reference to any prior art in this specification does not constitute an acknowledgement or implication that this prior art forms part of the common general knowledge in any jurisdiction, nor does it imply that this prior art could be reasonably understood by a person skilled in the art to be related to and / or combinable with other prior art. Summary of the Invention
[0013] The present invention provides a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide and a second polypeptide, wherein:
[0014] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and
[0015] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;
[0016] wherein the second polypeptide comprises the sequence of one or more adhesin binding motifs (ABMs), preferably wherein the ABMs correspond to some or all of the ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain;
[0017] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 21 (ABM2) and / or SEQ ID NO: 17 or 22 (AMB3) or a sequence at least 80% identical thereto,
[0018] More preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 21 (ABM2), SEQ ID NO: 14 or 20 (ABM1) and / or SEQ ID NO: 17 or 22 (ABM3) or a sequence at least 80% identical thereto,
[0019] Most preferably wherein the one or more ABMs comprise the sequence shown in SEQ ID NO: 16 or SEQ ID NO: 18 or SEQ ID NO: 19 or SEQ ID NO: 23 or any one of 26, 27, 28, 43, 44 or 45, or a sequence at least 80% identical thereto;
[0020] And among them:
[0021] a) the second polypeptide does not comprise: the sequence of a cleaved adhesin domain (CAD) or a portion thereof, preferably the sequence of a CAD having the sequence shown in SEQ ID NO: 12 or 13 or a sequence at least 80% identical thereto; and / or
[0022] b) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, preferably as shown in SEQ ID NO: 24, or a sequence at least 80% identical thereto.
[0023] Preferably, the chimeric or fusion protein comprises one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. The one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis may be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide, or the C-terminus of the second polypeptide. In certain embodiments, there may be at least two additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. In such embodiments, the two additional polypeptides may be located at the N-terminus of the second polypeptide, the C-terminus of the second polypeptide, or both the N-terminus and the C-terminus of the second polypeptide.
[0024] The one or more additional polypeptides may be linked to the first polypeptide or the second polypeptide of the chimeric or fusion protein, preferably via a linker of no more than 50 amino acids, or directly linked to the first polypeptide or the second polypeptide.
[0025] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0026] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0027] In any embodiment, the first polypeptide and the additional polypeptide comprise or consist of an amino acid sequence that is the active site of an Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis, or comprise or consist of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or wherein the amino acid sequences are identical. The first polypeptide and the additional polypeptide can be derived from the active site of a heterologous gingipain (e.g., a gingipain from a different strain of Porphyromonas gingivalis). The first polypeptide and the additional polypeptide may have amino acid sequences derived from different gingipains (e.g., wherein one of the polypeptides has an amino acid sequence from the active site of Kgp and the other has an amino acid sequence from the active site of Rgp; or alternatively, wherein one of the polypeptides has an amino acid sequence from the active site of RgpA and the other has an amino acid sequence from the active site of RgpB).
[0028] In a first aspect, the present invention provides a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide and a second polypeptide, wherein:
[0029] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto;
[0030] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;
[0031] wherein the second polypeptide comprises the sequence of one or more adhesin binding motifs (ABMs), preferably wherein the ABMs correspond to some or all of the ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain;
[0032] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 21 (ABM2) and / or SEQ ID NO: 17 or 22 (ABM3), or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto,
[0033] More preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 21 (ABM2), SEQ ID NO: 14 or 20 (ABM1) and / or SEQ ID NO: 17 or 22 (ABM3), or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto,
[0034] Most preferably wherein the one or more ABMs comprise the sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 18 or SEQ ID NO: 19 or SEQ ID NO: 23 or any one of 26, 27, 28, 43, 44 or 45, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto;
[0035] And among them:
[0036] a) the second polypeptide does not comprise a cleaved adhesin domain (CAD), said CAD preferably having the sequence shown in SEQ ID NO: 12 or 13, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto;
[0037] Optionally, the chimeric or fusion protein comprises one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto.
[0038] The one or more additional polypeptides comprising or consisting of the active site of the Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis can be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide, or the C-terminus of the second polypeptide. The one or more additional polypeptides can be linked to the first polypeptide or the second polypeptide of the chimeric or fusion protein, preferably via a linker of no more than 50 amino acids, or directly linked to the first polypeptide or the second polypeptide.
[0039] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0040] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0041] In any embodiment of the first aspect of the invention, the first polypeptide and the further polypeptide comprise or consist of an amino acid sequence that comprises the active site of an Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or comprise or consist of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or wherein the amino acid sequences are identical. The first polypeptide and the further polypeptide may be derived from the active site of a heterologous gingipain (e.g., a gingipain from a different strain of Porphyromonas gingivalis). The first polypeptide and the additional polypeptide may have amino acid sequences derived from different gingipains (e.g., wherein one of the polypeptides has an amino acid sequence from the active site of Kgp and the other has an amino acid sequence from the active site of Rgp; or alternatively, wherein one of the polypeptides has an amino acid sequence from the active site of RgpA and the other has an amino acid sequence from the active site of RgpB).
[0042] In a particularly preferred embodiment of the first aspect of the invention, the chimeric or fusion protein comprises or consists of an amino acid sequence as shown in either of 41 or 42, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% thereof.
[0043] In a second aspect, the present invention provides a chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis, the protein comprising a first polypeptide linked to a second polypeptide, wherein:
[0044] A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and
[0045] B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis;
[0046] wherein the second polypeptide comprises the sequence of one or more adhesin binding motifs (ABMs), preferably wherein the ABMs correspond to some or all of the ABMs between the DUF2436 domain and the cleaved adhesin domain (CAD) of Porphyromonas gingivalis gingipain;
[0047] Preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 21 (ABM2) and / or SEQ ID NO: 17 or 22 (ABM3) or a sequence at least 80% identical thereto,
[0048] More preferably wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 21 (ABM2), SEQ ID NO: 14 or 20 (ABM1) and / or SEQ ID NO: 17 or 22 (ABM3) or a sequence at least 80% identical thereto,
[0049] Most preferably wherein the one or more ABMs comprise the sequence shown in SEQ ID NO: 16 or any one of SEQ ID NO: 18, 19 or 23 or SEQ ID NO: 26, 27, 28 or a sequence at least 80% identical thereto;
[0050] And among them:
[0051] a) the second polypeptide does not comprise: a sequence of a cleaved adhesin domain (CAD) or a portion thereof, the CAD preferably having the sequence shown in SEQ ID NO: 12 or 13 or a sequence at least 80% identical thereto; and
[0052] b) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, preferably as shown in SEQ ID NO: 24, or a sequence at least 80% identical thereto.
[0053] As used herein, an amino acid sequence substantially corresponding to the full length of a DUF2436 domain, or a sequence that is at least 80% identical thereto, refers to a sequence that comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the length of the DUF2436 domain of Arg-gingipain or Lys-gingipain.
[0054] In preferred embodiments, the amino acid sequence of the DUF2436 domain of Arg-gingipain or Lys-gingipain is the sequence shown in SEQ ID NO:24, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0055] Most preferably, the second polypeptide comprises or consists of the sequence shown in SEQ ID NO: 26, 27 or 28, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0056] Preferably, the chimeric or fusion protein comprises one or more additional polypeptides comprising the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, or consisting thereof. The one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis may be located at the N-terminus of the first polypeptide, at the C-terminus of the first polypeptide, at the N-terminus of the second polypeptide, or at the C-terminus of the second polypeptide. The one or more additional polypeptides may be linked to the first polypeptide or the second polypeptide of the chimeric or fusion protein, preferably via a linker of no more than 50 amino acids, or directly linked to the first polypeptide.
[0057] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0058] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0059] In any embodiment, the first polypeptide and the additional polypeptide comprise or consist of an amino acid sequence that is the active site of an Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis, or comprise or consist of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or wherein the amino acid sequences are identical. The first polypeptide and the additional polypeptide can be derived from the active site of a heterologous gingipain (e.g., a gingipain from a different strain of Porphyromonas gingivalis). The first polypeptide and the additional polypeptide may have amino acid sequences derived from different gingipains (e.g., wherein one of the polypeptides has an amino acid sequence from the active site of Kgp and the other has an amino acid sequence from the active site of Rgp; or alternatively, wherein one of the polypeptides has an amino acid sequence from the active site of RgpA and the other has an amino acid sequence from the active site of RgpB).
[0060] In a particularly preferred embodiment of the second aspect of the invention, the chimeric or fusion protein comprises or consists of an amino acid sequence as shown in any one of SEQ ID NO: 29, 30, 31, 32, 33, 34, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% thereof.
[0061] In any embodiment of any aspect of the present invention, the chimeric or fusion protein consists of or essentially consists of the sequence of the first polypeptide and the second polypeptide as defined herein. It should therefore be understood that the chimeric or fusion protein includes an arrangement or configuration of domains that differ from the configuration of those domains in the naturally occurring gingipain polyprotein sequence. In other words, the first polypeptide and the second polypeptide and the domains therein have a spatial configuration that differs from that of the naturally occurring gingipain polyprotein.
[0062] In any embodiment of any aspect of the invention, the first polypeptide and the second polypeptide are linked. The first polypeptide and the second polypeptide can be linked directly, via a linker, or via a polypeptide sequence of no more than 100, preferably no more than 50, amino acids. Preferably, the first polypeptide and the second polypeptide are linked directly, or via no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids. Most preferably, the first polypeptide and the second polypeptide are directly linked.
[0063] In any embodiment of any aspect of the invention, the C-terminal residue of the first polypeptide can be linked to the N-terminal residue of the second polypeptide directly, through a linker, or through a polypeptide sequence of no more than 50 amino acids. Alternatively, the N-terminal residue of the first polypeptide can be linked to the C-terminal residue of the second polypeptide directly, through a linker, or through a polypeptide sequence of no more than 50 amino acids.
[0064] In any aspect of the invention, the DUF2436 domain (if present) and the ABM domain derived from Arg-gingipain or Lys-gingipain can be directly joined or joined via a linker or via a polypeptide sequence. Preferably, the DUF2436 domain and the ABM domain are connected by a short linker sequence comprising about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids. In particularly preferred embodiments, the DUF domain and the ABM domain are connected by a short linker sequence of no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids.
[0065] In a preferred embodiment, the DUF2436 domain and the ABM domain (having representative amino acid sequences of SEQ ID NOs: 24 or 25 and 18, respectively) can be linked by a peptide sequence having the amino acid sequence EVEDDSP.
[0066] In any embodiment, the additional polypeptide can be joined to the chimeric or fusion protein comprising the first polypeptide and the second polypeptide directly or through a linker. In embodiments where the additional polypeptide is joined to the C-terminal region of the fusion protein via the second polypeptide, preferably the C-terminus of the second polypeptide is directly joined to the N-terminus of the additional polypeptide. (For example, the C-terminus of the adhesin domain is preferably directly joined to the N-terminus of the active site amino acid sequence).
[0067] In any embodiment of any aspect of the present invention, the linker region is no more than 15 amino acids, and preferably more than 2 amino acid amino acid sequences. Suitable linkers known in the art for protein constructs include linkers with minimal effect on solubility. Useful linkers include glycine-serine (GlySer) linkers, which are well known in the art and include glycine and serine units combined in various orders. Examples include but are not limited to (GS), (GSGGS)n, (GGGS)n, and (GGGGS)n, where n is an integer at least one, typically an integer between 1 and about 10, such as between 1 and about 8, between 1 and about 6, or between 1 and about 5. Other useful linkers include DSSG, DSSGAS, KLDSSG, or other linkers described herein. In certain embodiments, the linker region can be derived from a natural gingipain polyprotein sequence.
[0068] The invention also provides a nucleic acid encoding a chimeric or fusion protein as defined herein.
[0069] Preferably, the nucleic acid has a nucleotide sequence encoding any one or more of the amino acid sequences defined in Table 1 herein.
[0070] In any embodiment, such nucleic acid is contained in an expression construct, wherein the nucleic acid is operably linked to a promoter.Such expression constructs can be present in a vector (e.g., a plasmid) or a viral vector.
[0071] The present invention also provides a cell comprising a nucleic acid or nucleic acid vector as described herein. Examples of cells of the present invention include bacterial cells, yeast cells, insect cells or mammalian cells. Preferably, the cell is isolated, substantially purified or recombinant.
[0072] The present invention also provides a composition comprising a chimeric or fusion protein as described herein, optionally in combination with a pharmaceutically acceptable carrier.
[0073] The composition may further include an adjuvant for enhancing the immune response to the chimeric or fusion protein.
[0074] Therefore, the present invention further provides a vaccine or immunostimulatory composition for inducing an immune response against Porphyromonas gingivalis in a subject, the composition comprising:
[0075] i) an immunogen in the form of a chimeric or fusion protein as described herein, and
[0076] ii) an adjuvant for enhancing the subject's immune response to the immunogen.
[0077] Preferably, the only immunogen provided in the composition, vaccine or immunostimulatory composition of the invention is a chimeric or fusion protein as described herein.
[0078] The present invention also provides a method for inducing an immune response to Porphyromonas gingivalis in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein, vaccine or immunostimulatory composition as described herein.
[0079] The present invention also provides a method of inducing a humoral immune response to Porphyromonas gingivalis in a subject, the method comprising administering to the subject a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein.
[0080] Preferably, the induced immune response comprises a switch from a Th1 to a Th2 immune response.
[0081] It will be understood that in any embodiment, the immune response elicited by administering the chimeric or fusion proteins described herein (or vaccines or other compositions comprising the chimeric or fusion proteins) is preferably antigen-specific. Thus, in preferred embodiments, the methods and compositions and chimeric proteins described herein are used to induce an immune response, preferably a protective immune response, to a Porphyromonas gingivalis gingipain antigen.
[0082] In any embodiment, the compositions, chimeric proteins, and methods of the present invention can be used to enhance an immune response (eg, a protective immune response) to P. gingivalis in a subject.
[0083] The present invention also provides a method of immunizing a subject against infection by P. gingivalis, the method comprising administering to the subject a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein.
[0084] In any embodiment, a subject who has received or been administered a chimeric or fusion protein of the invention, or a composition or vaccine comprising the chimeric or fusion protein, has an increased level of protection against infection with Porphyromonas gingivalis or the severity of one or more symptoms of infection with Porphyromonas gingivalis compared to a subject who has not received the protein, composition, or vaccine.
[0085] Still further, the present invention provides a method for treating a Porphyromonas gingivalis infection in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein, thereby treating the Porphyromonas gingivalis infection in the subject.
[0086] The present invention provides a method for reducing the severity of or minimizing symptoms associated with Porphyromonas gingivalis infection, the method comprising administering to an individual in need thereof a chimeric or fusion protein, composition, vaccine, or immunostimulatory composition as defined herein, wherein the symptoms are selected from the group consisting of swollen or edematous gums, gums that bleed easily, receding gums, periodontal pockets around the teeth, loss of tooth-supporting tissue (periodontal ligament, cementum, and / or alveolar bone), pus between the gums and teeth, and gingivitis.
[0087] The present invention also provides a method for treating a Porphyromonas gingivalis-associated disease in a subject, the method comprising administering to an individual in need thereof a chimeric or fusion protein, composition, vaccine, or immunostimulatory composition as defined herein. Preferably, the Porphyromonas gingivalis-associated disease comprises periodontal disease.
[0088] The present invention provides a method of treatment comprising administering a chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention, and may further comprise administering one or more of the following: an antimicrobial compound, an anti-inflammatory agent.
[0089] The present invention also provides the use of a chimeric or fusion protein as defined herein for the preparation of a medicament for:
[0090] Inducing an immune response (preferably a protective immune response) against Porphyromonas gingivalis in a subject;
[0091] ●Immunize subjects against Porphyromonas gingivalis infection;
[0092] Treating Porphyromonas gingivalis infection in subjects;
[0093] Minimizing or reducing the severity of one or more symptoms of a P. gingivalis infection; or
[0094] Treating a Porphyromonas gingivalis-associated disease in a subject.
[0095] The present invention also provides a chimeric or fusion protein, composition, vaccine or immunostimulatory composition as defined herein for use in:
[0096] Inducing an immune response (preferably a protective immune response) against Porphyromonas gingivalis in a subject;
[0097] ●Immunize subjects against Porphyromonas gingivalis infection;
[0098] Treating Porphyromonas gingivalis infection in subjects;
[0099] Minimizing or reducing the severity of one or more symptoms of a P. gingivalis infection; or
[0100] Treating a Porphyromonas gingivalis-associated disease in a subject.
[0101] In any method, use, or protein, composition, or vaccine for use according to the present invention, the subject may be any subject already infected with or at risk of being infected with P. gingivalis. The subject may be a human. The subject may be a veterinary subject, such as a companion animal having an infection with or at risk of being infected with P. gingivalis.
[0102] The present invention also provides a method for obtaining antibodies against Porphyromonas gingivalis, the method comprising administering a chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal. Preferably, the method further comprises isolating the antibodies from the animal (e.g., by extracting from the animal's blood) or from its eggs (in the case where the animal is an avian species, preferably a chicken).
[0103] The present invention also provides an antibody preparation comprising antibodies against Porphyromonas gingivalis, wherein the antibody preparation is obtained by administering the chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal, and isolating the antibodies from the animal or its eggs.
[0104] Antibodies against P. gingivalis can be used therapeutically to eliminate or reduce P. gingivalis infection, or prophylactically to prevent or reduce the severity of P. gingivalis infection.
[0105] The present invention also provides a kit comprising a composition comprising a chimeric or fusion protein as defined herein, wherein optionally the kit comprises one or more cytokines and / or adjuvants in a sealed container.
[0106] Preferably, the kit comprises a label or package insert indicating that the composition is for immunizing an individual, optionally wherein the label or package insert contains instructions for use.
[0107] Throughout this specification, unless the context requires otherwise, the words "comprise / comprises / comprising" should be understood to imply the inclusion of the stated step or element or group of steps or elements, but not the exclusion of any other step or element or group of steps or elements. Thus, the use of the terms "comprising" and the like indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present. "Consisting of" means including and limited to whatever follows the phrase "consisting of." Thus, the phrase "consisting of" indicates that the listed elements are required or mandatory, and other elements may not be present. "Consisting essentially of" means including any elements listed after the phrase, and is limited to other elements that do not interfere with or facilitate the activities or actions specified for the listed elements in this disclosure. Thus, the phrase "consisting essentially of indicates that the listed elements are required or mandatory, but other elements (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more additional amino acid residues at the N-terminus or C-terminus of the polypeptide sequence) are optional and may or may not be present, depending on whether they affect the activity or action of the listed elements.
[0108] Further aspects of the present invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, which is given by way of example and with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0109] Figure 1 A. Mouse periodontitis model - therapeutic vaccination. B. Schematic diagram showing the domain structure of the Kgp gingipain multiprotein and components derived therefrom used to generate the chimeric or fusion proteins of the present invention.
[0110] Figure 2 A. SDS-PAGE of Escherichia coli (E. coli) fractions expressing recombinant variants with or without the K1 domain and containing full-length or truncated DUF domains. Low temperature and low IPTG conditions were used. Full-length DUF is important for solubility. Full-length K1 is detrimental to solubility. B. Native PAGE of the chimeric constructs KDA and KDAK1 in the presence or absence of DTT. Addition of the K1 domain to KDA reduces solubility.
[0111] Figure 3 Bone loss study. Statistical analysis – One-way ANOVA and post hoc Dunnet's T3. #Significantly different from the control challenge group.
[0112] Figure 4 Antigen isotype responses to heat-killed whole cells of P. gingivalis (individual sera). Naive = control unchallenged. P. gingivalis = control challenge with P. gingivalis. Chimera = KDcAK1n antigen. Amox = amoxicillin.
[0113] Figure 5 Statistical analysis of bone loss study – one-way ANOVA and post hoc Dunnett T3. #p<0.01; ##p<0.05 (T test) significantly different from the control challenge group.
[0114] Figure 6 Bone loss study. S = soluble fraction; Urea = urea used for purification; AC = affinity column purification; IB = inclusion bodies; Batch = batch purification method. Statistical analysis: One-way ANOVA with post hoc Dunnett's T3. #p < 0.01, significantly different from the control-challenge group.
[0115] Figure 7 Bone loss was studied after immunization of animals with various fusion protein constructs. Statistical analysis: One-way ANOVA and post hoc Dunnett's T3, significant differences from control challenge group, #p<0.05##p<0.01###p<0.001####p<0.0001.
[0116] Sequence information
[0117] Table 1: Sequence information
[0118]
[0119]
[0120]
[0121]
[0122] DETAILED DESCRIPTION
[0123] It should be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the various features mentioned or evident in the text or drawings. All these different combinations constitute various alternative aspects of the invention.
[0124] Reference will now be made in detail to certain embodiments of the present invention. Although the present invention will be described in conjunction with the embodiments, it will be understood that it is not intended to limit the invention to those embodiments. On the contrary, the present invention is intended to cover all alternatives, modifications and equivalents that may be included within the scope of the present invention as defined in the claims.
[0125] Those skilled in the art will recognize that many methods and materials similar or equivalent to the methods or materials described herein can be used to practice the present invention. The present invention is in no way limited to the methods and materials described. It should be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or apparent in the text or drawings. All of these different combinations constitute various alternative aspects of the present invention.
[0126] All patents and publications mentioned herein are incorporated by reference in their entirety.
[0127] For the purpose of interpreting this specification, terms used in the singular will also include the plural form, and vice versa.
[0128] In the work leading to the present invention, the inventors investigated various chimeric or fusion proteins for inducing an immune response to P. gingivalis, as well as methods for the large-scale production of such chimeras for use as vaccine candidates.
[0129] The present inventors have identified various problems associated with the large-scale preparation and production of chimeric or fusion proteins derived from components of Porphyromonas gingivalis gingipain. First, the chimeric or fusion proteins described in the prior art are difficult to produce in sufficiently high quantities as soluble proteins. More specifically, the chimeric proteins of the prior art are typically produced in inclusion bodies in Escherichia coli, making it challenging to produce large quantities of soluble protein for downstream clinical product development.
[0130] The reduced solubility when produced in E. coli also significantly increases the time and scale of production, and the protein suffers from poor stability once solubilized and refolded from inclusion bodies.
[0131] Thus, the present invention relates to improved designs of chimeric or fusion proteins for inducing an immune response to P. gingivalis, as well as methods and uses comprising such improved designs.
[0132] In any embodiment, the chimeric or fusion protein of the present invention has improved solubility and / or stability compared to chimeric or fusion proteins described in the prior art. When it comes to large-scale production of fusion proteins for use in clinical settings, improved solubility and / or stability provides significant advantages.
[0133] In alternative embodiments, the chimeric or fusion proteins of the present invention have a reduced tendency to aggregate compared to prior art chimeric or fusion proteins. Aggregation can hinder large-scale preparation and production of therapeutic / prophylactic proteins. Thus, reducing the aggregation tendency of the chimeric proteins of the present invention provides a significant improvement over prior art chimeric proteins used to induce an immune response to P. gingivalis.
[0134] Still further, in any embodiment, the chimeric or fusion protein of the present invention has increased immunogenicity compared to prior art chimeric or fusion proteins.
[0135] Thus, the present inventors have identified various novel methods for obtaining chimeric or fusion proteins for inducing an immune response to P. gingivalis, and which have resulted in chimeric or fusion proteins having one or more advantages over the prior art.
[0136] The present inventors believe that one or more of the novel methods described herein for producing chimeric or fusion proteins for inducing an immune response to Porphyromonas gingivalis may provide advantages including: easier preparation of suitable immunogenic compositions for inducing an immune response to Porphyromonas gingivalis; extended shelf life and / or improved immunogenicity.
[0137] Gingipains
[0138] The pathogenicity of P. gingivalis is attributed to numerous surface-associated virulence factors, including cysteine proteases (gingipasins), pili, heme-binding proteins, and outer membrane transporters. Specifically, the extracellular Arg-specific and Lys-specific proteases 'gingipasins' (RgpA / B and Kgp) of P. gingivalis are considered major virulence factors, crucial for colonization, penetration into host tissues, dysregulation of the immune response, dysbiosis, and disease.
[0139] Gingival proteases, particularly the Lys-specific protease Kgp, are essential for P. gingivalis-induced alveolar bone resorption in a mouse model of periodontitis. Gingival proteases are also found in gingival tissue at sites of severe periodontitis, at high concentrations near subgingival plaques and at lower concentrations at distal sites deep within the gingival tissue. Lys- and Arg-specific proteases have been shown to degrade a variety of host proteins in vitro, such as fibrinogen, fibronectin, and laminin. Plasma host defense and regulatory protease inhibitors α-trypsin, α2-macroglobulin, antichymotrypsin, antithrombin III, and antiplasmin are also degraded by P. gingivalis Lys- and Arg-proteases. This has led to the development of a compelling mechanism to explain the key role played by P. gingivalis in the development of chronic periodontitis.
[0140] The RgpA, RgpB, and Kgp genes all encode an N-terminal signal peptide of approximately 22 amino acids in length, an unusually long propeptide of approximately 200 amino acids in length, and a catalytic domain of approximately 480 amino acids in length. The C-terminus of the catalytic domain is a large hemagglutinin-adhesin (HA) domain, which contains an adhesin binding domain (ABM, or five different sequences have been described), a "domain of unknown function" (called DUF2436, defined as a conserved Pfam domain of unknown function; IPR018832), and a C-terminal adhesin domain or a cleaved adhesin domain (or CAD). The specific arrangement of the ABM, DUF, and CAD differs between Kgp and RgpA / B.
[0141] The domain architecture of the Kgp polyprotein is Figure 1 B. For example, Kgp includes (N-terminus to C-terminus): a catalytic domain, a first ABM (ABM1), DUF2436, a domain including ABM2, ABM1, ABM3, two CAD domains (designated K1 and K2), an additional domain including ABM1 and ABM2, an additional CAD domain (designated K3), ABM2, and a C-terminal domain.
[0142] As used herein, references to ABMs 1, 2, and 3 will be understood to generally refer to the ABMs found in the order ABM2, ABM1, and ABM3 in the sequence immediately following the C-terminus of DUF2436 of Kgp, e.g. Figure 1 Depicted by B.
[0143] The catalytic domains of RgpB and RgpA share a high degree of sequence homology. However, RgpB lacks the HA domain and is located in the outer membrane as a monomer. Some of the HA domains have been alternatively described as C-terminal adhesin domains or cleaved adhesin domains (CAD), and some are DUF ("domain of unknown function") 2436 domains (conserved Pfam domain of unknown function; IPR018832).
[0144] RgpA and Kgp precursor proteins are cut into multiple domains that maintain non-covalent association to form a large outer membrane protein complex. Therefore, in vivo, Arg-specific proteases and Lys-specific proteases have been found in the complex of non-covalently associated proteases and adhesin cell associations. A type of such complex is named RgpA-Kgp protease-adhesin complex (previously known as PrtR-PrtK protease-adhesin complex). The complex is composed of a cysteine protease stable with 45kDa Arg specific calcium and seven sequence-related adhesin domains.
[0145] As used herein, the Lys-gingipain catalytic domain may also be referred to as the KAS domain or the PAS domain. As used herein, the Arg-gingipain catalytic domain may also be referred to as the RAS domain or the PAS domain. Typically, the catalytic domain of Lys-gingipain or Arg-gingipain is located in the approximately 480 amino acid region of the N-terminus of the protein. The active site in the catalytic domain is typically located at amino acid residues 426-446 (for RgpA) and 432-453 (for Kgp). Table 1 lists exemplary active site peptides found in the catalytic domain, such as SEQ ID NO: 1-11.
[0146] As used herein, the adhesin domain of the Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis will be understood to refer generally to the region of the Arg-gingipain or Lys-gingipain located C-terminal to the catalytic or active site domain. The adhesin domain (also referred to as the HA domain) generally includes a domain of unknown function (DUF) domain (particularly the conserved Pfam domain of unknown function of DUF 2436; IPR018832) and several adhesin binding motif (ABM) domains as well as a cleaved adhesin domain (CAD).
[0147] First polypeptide
[0148] The chimeric or fusion protein of the present invention comprises a first polypeptide comprising or consisting of the amino acid sequence of the active site of the Arg-X protease or Lys-X protease of Porphyromonas gingivalis (also referred to herein as Arg-gingipain or Lys-gingipain, respectively), or a sequence that is at least 80% identical thereto.
[0149] In any embodiment, the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0150] Improved immunogenicity
[0151] Preferably, the chimeric or fusion protein comprises one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. The one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis may be located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide, or the C-terminus of the second polypeptide. The one or more additional polypeptides may be linked to the first polypeptide or the second polypeptide of the chimeric or fusion protein, preferably via a linker of no more than 50 amino acids, or directly linked to the first polypeptide.
[0152] The one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0153] In any embodiment, the first polypeptide comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis and the additional polypeptide comprise or consist of the same amino acid sequence or sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each other.
[0154] In preferred embodiments, the chimeric or fusion protein of the present invention comprises no more than 2, no more than 3, or no more than 4 polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto. Preferably, the chimeric or fusion protein of the present invention has less than 5, more preferably less than 4, and most preferably less than 3 polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence at least 80% identical thereto.
[0155] The second polypeptide
[0156] The chimeric or fusion protein of the present invention comprises a second polypeptide comprising or consisting of the amino acid sequence of the adhesin domain of the ArgX protease or Lys-X protease of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto.
[0157] It will be understood that the second polypeptide will typically include at least one sequence corresponding to one or more of the adhesin binding motifs (ABMs), which are recognized domains / motifs in the adhesin domains of the ArgX protease or Lys-X proteases of Porphyromonas gingivalis (e.g., Kgp and RgpA).
[0158] Five ABMs (ABMs 1-5) have been defined for Kgp and RgpA. Exemplary sequences of these ABMs are shown in Table 1.
[0159] Typically, the second polypeptide comprises more than one ABM, preferably wherein the second polypeptide comprises at least ABM1 and ABM2, or a sequence at least 80% identical to each of ABM1 or ABM2. The second polypeptide may also comprise the sequence of ABM3 or a sequence at least 80% identical thereto.
[0160] It should also be understood that the arrangement of the ABM peptides in the second polypeptide need not correspond to the arrangement of the ABM peptides found in naturally occurring adhesin domains. For example, the ABM peptides can be arranged in the second polypeptide in the sequence (N-terminal to C-terminal) ABM1, ABM2, ABM3, etc. Alternatively, the ABM peptides can be arranged to reflect the arrangement in naturally occurring adhesin domains (such as ABM2, ABM1, and ABM3), such as that found in adhesin domain 1 of Kgp.
[0161] Still further, the ABMs in the second polypeptide may be arranged contiguously, or may be separated from each other by an amino acid sequence of no more than 50 amino acids. It will be understood by those skilled in the art that the spacing between ABMs is not important in the design of the chimeric or fusion proteins of the present invention.
[0162] In any embodiment, the second polypeptide comprises the amino acid sequence as shown in SEQ ID NO: 16, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0163] In any embodiment, the second polypeptide comprises the amino acid sequence as shown in SEQ ID NO: 19, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0164] In any embodiment, the second polypeptide comprises the amino acid sequence as shown in SEQ ID NO: 18 or 23, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0165] In any embodiment, the second polypeptide comprises an amino acid sequence as shown in SEQ ID NO: 26, 27 or 28 or 43, 44 or 45, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0166] The present inventors have determined that prior art approaches involving simply selecting various domains found in naturally occurring gingipains for use in chimeric or fusion proteins often result in proteins that express poorly in recombinant systems and tend to be expressed as insoluble proteins (e.g., in inclusion bodies in E. coli).
[0167] With reference to the examples of this specification, the present inventors have recognized that the sequence shown in SEQ ID NO: 13 (i.e., a truncated form of the CAD domain) represents how the Kgp polyprotein undergoes proteolytic processing and assembly on the cell surface. Therefore, the inclusion of such a sequence is considered to be crucial for inducing an immune response to Porphyromonas gingivalis. However, the present inventors surprisingly discovered that, when present, this sequence resulted in poor solubility of the recombinant protein and the formation of inclusion bodies when expressed in E. coli.
[0168] The present inventors attempted to remedy this problem by including the complete sequence of CAD in a fusion protein. Surprisingly, this did not improve solubility and in fact resulted in lower solubility.
[0169] Thus, the present inventors have found that the inclusion of sequences corresponding to one or more cleaved adhesin domains (CAD) or parts thereof contributes to reducing the solubility of the proposed chimeric proteins and vaccine compositions derived from gingipain sequences.
[0170] Therefore, in a particularly preferred embodiment of the present invention, the second polypeptide does not include the sequence shown in SEQ ID NO: 13 or a sequence that is at least 80% identical thereto.
[0171] Alternatively, the second polypeptide does not include the sequence as shown in SEQ ID NO: 12, or a sequence at least 80% identical thereto, or a portion thereof.
[0172] The present inventors also discovered that when the chimeric or fusion protein of the present invention includes only a portion of the DUF2436 domain (ie, an N-terminally truncated DUF2436 domain), the solubility of the chimeric or fusion protein of the present invention is reduced.
[0173] With reference to the examples of this specification, the present inventors have recognized that prior art approaches to P. gingivalis vaccine design include N-terminal truncated forms of the DUF2436 domain. Although the truncated DUF2436 domain represents how the Kgp polyprotein undergoes proteolytic processing and assembly on the cell surface, the present inventors have discovered that providing a full-length sequence of the DUF2436 domain (i.e., including the N-terminal portion of the DUF2436 domain) significantly improves the production of soluble recombinant protein.
[0174] Thus, in preferred embodiments, the second polypeptide in the chimeric or fusion protein of the invention comprises residues 1 to 37 of the DUF2436 domain, preferably wherein the chimeric protein comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, or a sequence that is at least 80% identical thereto.
[0175] As used herein, an amino acid sequence substantially corresponding to the full length of a DUF2436 domain, or a sequence at least 80% identical thereto, refers to a sequence that comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the length of the DUF2436 domain of Arg-gingipain or Lys-gingipain.
[0176] Preferably, the DUF2436 domain comprises the sequence shown in SEQ ID NO: 24, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0177] Linking of the first polypeptide to the second polypeptide
[0178] In the chimeric or fusion proteins of the present invention, the C-terminal residue of the first polypeptide can be covalently linked to the N-terminal residue of the second polypeptide (corresponding to the adhesin domain polypeptide), or the N-terminal residue of the first peptide can be covalently linked to the C-terminal residue of the second polypeptide (corresponding to the adhesin domain polypeptide). In this arrangement, the first peptide and the adhesin domain polypeptide are said to be "directly linked" or "adjacent."
[0179] In other embodiments, the chimeric or fusion protein comprises a linker for connecting the first peptide to the adhesin domain polypeptide.The linker can be any linker capable of joining a peptide to a polypeptide, including both amino acid linkers and non-amino acid linkers.
[0180] Preferably, the linker is non-immunogenic. Typically, the linker comprises amino acids and may therefore be referred to as a peptide linker.
[0181] Joints are typically peptides with a length of up to 20 amino acids, although they may be longer. The term "with ... connected" or "with ... fused" refers to the covalent bond (for example, peptide bond) formed between the two parts. Therefore, in the context of the present invention, the length of a joint can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 or more amino acids. For example, the chimeric or fusion protein provided herein can include a joint between a first polypeptide and a second polypeptide (such as between the N-terminal of the second polypeptide and the C-terminal of the first polypeptide), wherein the first polypeptide includes the amino acid sequence of a Porphyromonas gingivalis gingivalisin active domain or is composed of it, and the second polypeptide is corresponding to the adhesin domain of a Porphyromonas gingivalis gingivalisin. The advantage of this type of joint is that it can make the different polypeptides of the fusion protein more likely to fold independently and show expected behavior. Suitable linkers may be up to 50 amino acids in length, although fewer than 20, fewer than 15, or fewer than five amino acids are preferred. The linker may serve to place the first peptide and the adhesin domain polypeptide in closer spatial arrangement than is typically observed in the P. gingivalis trypsin-like enzyme. Alternatively, it may separate the first polypeptide from the second polypeptide (corresponding to the adhesin domain polypeptide).
[0182] Suitable joints for protein constructs known in the art include joints having minimal effect on solubility.Joints can be any joints known to persons skilled in the art, and can be flexible joints (such as joints of repeat sequences including glycine residues and serine residues), rigid joints (such as joints including glutamic acid residues and lysine residues, joints flanking alanine repeat sequences) and / or cleavable joints (such as sequences susceptible to protease cleavage).The example of such joints is known to persons skilled in the art, and for example, in Chen et al., (2013) " Advanced Drug Delivery Reviews ", 65: described in 1357-1369.
[0183] Useful linkers include glycine-serine (GlySer) linkers, which are well known in the art and include glycine and serine units combined in various orders. Examples include, but are not limited to, (GS), (GSGGS)n, (GGGS)n, and (GGGGS)n, where n is an integer of at least one, typically an integer between 1 and about 10, such as between 1 and about 8, between 1 and about 6, or between 1 and about 5.
[0184] In some embodiments, the peptide linker can include amino acid glycine and serine of various lengths and combinations. In some aspects, the peptide linker can include sequence Gly-Gly-Ser (GGS), Gly-Gly-Gly-Ser (GGGS) or Gly-Gly-Gly-Gly-Ser (GGGGS) and variants or repetitive sequences thereof. In some aspects, the peptide linker can include amino acid sequence GGGGS (joint with a length of 6 amino acids) or even longer. The linker can be a series of repeated glycine and serine residues (GS) of different lengths, i.e., (GS)n, where n is any number from 1 to 15 or greater. For example, the linker can be (GS)3 (i.e., GSGSGS) or longer (GS)11 or longer. It should be understood that n can be any number comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more. The fusion protein with the linker of such length is included within the scope of the present invention. Similarly, the linker can be a series of repeated glycine residues separated by serine residues. For example, (GGGGS)3 (ie, the linker may comprise the amino acid sequence GGGGSGGGGSGGGGS(G4S)3) and variants thereof.
[0185] In one embodiment, the peptide linker can comprise the amino acid sequence GGGGS (a linker of 6 amino acids in length) or even longer. The linker can be a series of repeated glycine and serine residues (GS) of varying lengths, i.e., (GS)n, where n is any number from 1 to 15 or greater. For example, the linker can be (GS)3 (i.e., GSGSGS) or longer (GS)11 or longer. It should be understood that n can be any number comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more.
[0186] Other useful linkers include DSSG, DSSGAS, KLDSSG, and variants thereof. Examples of other suitable linkers are described in Chen et al. (2013) Advanced Drug Delivery Reviews, 65: 1357-1369.
[0187] Chimeric or fusion proteins and recombinant proteins
[0188] Chimeric or fusion proteins of the present invention can be prepared by any of a variety of conventional techniques, although recombinant techniques are typically used to prepare the polypeptides.
[0189] In the case of recombinant polypeptides, a DNA fragment encoding the desired peptide can be subcloned into an appropriate vector using well-known molecular genetic techniques (see, e.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory, 1982); Sambrook et al., Molecular Cloning A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory, 1989). The fragment can be transcribed, and the polypeptide subsequently translated in vitro. Commercially available kits (e.g., as prepared by Clontech, Palo Alto, Calif.; Amersham Pharmacia Biotech, Piscataway, NJ) can also be used. Inc., Piscataway, NJ); Invitrogen, Carlsbad, Calif., etc. The polymerase chain reaction can optionally be used to manipulate nucleic acids.
[0190] A "fragment" is a portion of a polypeptide of the invention that retains substantially similar functional activity or substantially the same biological function or activity as the polypeptide, as can be determined using the assays described herein.
[0191] "Percent (%) amino acid sequence identity" or "percent (%) identity" with respect to polypeptide sequences (i.e., polypeptides of the invention as defined herein) is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular polypeptide of the invention, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Reference herein to a variant having "at least x% sequence identity" to a sequence means that the variant is at least x% identical to the sequence.
[0192] In various aspects and embodiments of the present invention, the defined polypeptides are described by reference to variants having at least 80% homology or higher homology to a reference sequence. Percent homology (%) generally refers to the polypeptides of the invention as defined herein and is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular polypeptide of the invention, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percent sequence identity and not considering any conservative substitutions as part of the sequence identity.
[0193] The amino acids glycine, alanine, valine, leucine, and isoleucine are often interchangeable (amino acids with aliphatic side chains). Of these possible substitutions, it is preferred to use glycine and alanine as interchangeable substitutions (due to their relatively short side chains), and to use valine, leucine, and isoleucine as interchangeable substitutions (due to their larger, hydrophobic, aliphatic side chains). Other amino acids that are often interchangeable include: phenylalanine, tyrosine, and tryptophan (amino acids with aromatic side chains); lysine, arginine, and histidine (amino acids with basic side chains); aspartic acid and glutamic acid (amino acids with acidic side chains); asparagine and glutamine (amino acids with amide side chains); and cysteine and methionine (amino acids with sulfur-containing side chains).
[0194] Substitutions of this nature are often referred to as "conservative" or "semi-conservative" amino acid substitutions.
[0195] Amino acid deletions or insertions can also be made relative to the native sequence of a P. gingivalis protein. Thus, for example, amino acids can be deleted that do not substantially affect the activity of the polypeptide, or at least do not eliminate such activity. Such deletions can be advantageous, particularly for longer polypeptides, as the overall length and molecular weight of the polypeptide can be reduced while still maintaining activity. This can allow the amount of polypeptide required for a particular purpose to be reduced, for example, allowing for lower dosage levels.
[0196] Amino acid insertions relative to the native polypeptide sequence may also be made. This may alter the properties of the polypeptides used in the invention (e.g. to enhance antigenicity).
[0197] Amino acid changes can be made using any suitable technique, for example by using site-directed mutagenesis or solid-state synthesis.
[0198] It will be appreciated that amino acid substitutions or insertions within the scope of the present invention may be made using naturally occurring or non-naturally occurring amino acids. Regardless of whether natural or synthetic amino acids are used, it is preferred that only L-amino acids are present.
[0199] Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared (non-limiting examples are described below). When amino acid sequences are aligned, the percentage of amino acid sequence identity between a given amino acid sequence A and (and / or for) a given amino acid sequence B (which can alternatively be expressed as a given amino acid sequence A having or including a certain percentage of amino acid sequence identity with (and / or for) a given amino acid sequence B) can be calculated as: percentage of amino acid sequence identity = X / Y100, where X is the number of amino acid residues scored as identical matches by the sequence alignment program or algorithm for the alignment of A and B, and Y is the total number of amino acid residues in B. If the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percentage of amino acid sequence identity between A and B will not be equal to the percentage of amino acid sequence identity between B and A.
[0200] When calculating the percent identity, the exact matches are usually counted. The determination of the percent identity between two sequences can be completed using a mathematical algorithm. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, as modified in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such algorithms are incorporated into the BLASTN and BLASTX programs of Altschul et al. (1990) J. Mol. Biol. 215:403. In order to obtain gapped alignments for comparison purposes, gapped BLAST (in BLAST 2.0) as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389 can be utilized. Alternatively, PSI-Blast can be used for iterative retrieval for detecting the distance relationship between two molecules. See the same people such as Altschul (1997). When utilizing BLAST, vacant BLAST and PSI-Blast programs, the default parameters of each program (e.g., BLASTX and BLASTN) can be used. It is also possible to manually compare by inspection. Another non-limiting example of a mathematical algorithm for sequence comparison is the ClustalW algorithm (Higgins et al. (1994) Nucleic Acids Research 22:4673-4680). ClustalW compares multiple sequences and aligns all amino acids or DNA sequences, and therefore can provide data on the sequence conservation of all amino acid sequences. The ClustalW algorithm is used in some commercially available DNA / amino acid analysis software packages, such as the ALIGNX module of the Vector NTI program suite (Invitrogen Corporation, Carlsbad, CA, of Carlsbad, California). After carrying out amino acid sequence alignment with ClustalW, percent amino acid identity can be estimated. A non-limiting example of a software program useful for analysis of ClustalW alignments is GENEDOC TM Or JalView (http: / / www.jalview.org / ). GENEDOC TMIt allows to evaluate the amino acid (or DNA) similarity and identity between multiple proteins. Another non-limiting example of a mathematical algorithm for sequence comparison is the algorithm of Myers and Miller (1988) "Computer Applications in Biological Sciences (CABIOS)" 4: 11-17. Such an algorithm is incorporated into the ALIGN program (Version 2.0), which is a GCG Wisconsin Genetics Software Package, Version 10 (available from Accelrys, Inc., 9685 Scranton Rd., San Diego, CA, USA). When comparing amino acid sequences using the ALIGN program, a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
[0201] The polypeptide ideally includes an amino terminus and a carboxyl terminus. The polypeptide may include a D-amino acid, an L-amino acid, or a mixture of a D-amino acid and an L-amino acid. However, the D-form of the amino acid is particularly preferred because polypeptides comprising a D-amino acid are expected to have greater retention of their biological activity in vivo.
[0202] As used herein, the term "conservative substitution" refers to replacing an amino acid present in the native sequence of a peptide with a naturally occurring or non-naturally occurring amino acid or a peptide mimetic having similar steric properties. If the side chain of the natural amino acid to be replaced is polar or hydrophobic, the conservative substitution should be with a naturally occurring amino acid, a non-naturally occurring amino acid, or a peptide mimetic moiety that is polar or hydrophobic (in addition to having the same steric properties as the side chain of the replaced amino acid).
[0203] Conservative amino acid substitution tables providing functionally similar amino acids are well known to those skilled in the art. The following six groups are examples of amino acids that can be considered conservative substitutions for each other:
[0204] 1) Alanine (A), serine (S), threonine (T);
[0205] 2) Aspartic acid (D), glutamic acid (E);
[0206] 3) Asparagine (N), glutamine (Q);
[0207] 4) Arginine (R), Lysine (K);
[0208] 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
[0209] 6) Phenylalanine (F), tyrosine (Y), tryptophan (W).
[0210] Since naturally occurring amino acids are generally grouped according to their properties, conservative substitutions of naturally occurring amino acids can be determined, taking into account the fact that replacing a charged amino acid with a spatially similar non-charged amino acid is considered a conservative substitution. In order to produce conservative substitutions by non-natural amino acids, amino acid analogs (synthetic amino acids) well known in the art can also be used. Naturally occurring amino acid peptide mimetics are well documented in the literature known to those skilled in the art, and non-natural (non-natural or unnatural) amino acids are further described below. When affecting conservative substitutions, the substituted amino acid should have a functional group in the side chain that is identical or similar to the original amino acid.
[0211] As used herein, the phrase "non-conservative substitution" or "non-conservative residue" refers to the replacement of an amino acid present in the parent sequence with another naturally occurring or non-natural amino acid having different electrochemical and / or steric properties. Thus, the side chain of the substituted amino acid may be significantly larger (or smaller) than the side chain of the substituted natural amino acid and / or may have a functional group with significantly different electronic properties than the substituted amino acid. Examples of such non-conservative substitutions include the replacement of alanine with phenylalanine or cyclohexylmethylglycine, the replacement of glycine with isoleucine, or the replacement of aspartic acid with -NH-CH[(-CH2)5-COOH]-CO-. Non-conservative substitutions include any mutation that is not considered conservative.
[0212] Non-conservative amino acid substitutions may result from changes in: (a) the structure of the amino acid backbone in the region of the substitution; (b) the charge or hydrophobicity of the amino acid; or (c) the bulk of the amino acid side chain. Substitutions generally expected to produce the greatest changes in protein properties are: (a) substitution of a hydrophilic residue for (or by) a hydrophobic residue; (b) substitution of proline for (or by) any other residue; (c) substitution of a residue with a large side chain (e.g., phenylalanine) for (or by) a residue without a side chain (e.g., glycine); or (d) substitution of a residue with a positively charged side chain (e.g., lysyl, arginyl, or histidyl) for (or by) an electronegative residue (e.g., glutamyl or aspartyl).
[0213] The change of native amino acid sequence to produce mutant polypeptide (such as by insertion, deletion and / or substitution) can be carried out in various ways known to those skilled in the art.For example, by connecting the synthetic oligonucleotide comprising modified site into an expression vector, site-specific mutation can be introduced. Alternatively, oligonucleotide-directed site-specific mutagenesis program can be used, as disclosed in: Walder et al., Gene 42:133 (1986); Bauer et al., Gene 37:73 (1985); Craik, Biotechniques, 12-19 (January 1995); and U.S. Patent No. 4,518,584 and No. 4,737,462. The preferred mode of introducing mutation is QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, Calif., California).
[0214] Any suitable expression vector (e.g., as described in Pouwels et al., Cloning Vectors: A Laboratory Manual (Elsevier, NY: 1985)) and a corresponding suitable host can be used to produce recombinant polypeptides. Expression hosts include, but are not limited to, bacterial species within the genera Escherichia, Bacillus, Pseudomonas, and Salmonella, mammalian or insect host cell systems, including baculovirus systems (e.g., as described in Luckow et al., Bio / Technology 6:47 (1988)), and established cell lines such as COS-7, C127, 3T3, CHO, HeLa, and BHK cell lines. It is understood by those skilled in the art that the choice of expression host affects the type of polypeptide produced. For example, the glycosylation of a polypeptide produced in yeast or mammalian cells (e.g., COS-7 cells) will differ from the glycosylation of a polypeptide produced in bacterial cells (e.g., E. coli).
[0215] Alternatively, the polypeptides of the present invention can be synthesized using standard peptide synthesis techniques well known to those of ordinary skill in the art (e.g., as summarized in Bodanszky, Principles of Peptide Synthesis (Springer-Verlag, Heidelberg: 1984)). Specifically, the polypeptides can be synthesized using solid phase synthesis procedures (see, for example, Merrifield, J. Am. Chem. Soc. 85: 2149-54 (1963); Barany et al., Int. J. Peptide Protein Res. 30: 705-739 (1987); and U.S. Pat. No. 5,424,398). If desired, this can be accomplished using an automated peptide synthesizer. For example, removal of t-butyloxycarbonyl (t-BOC) or 9-fluorenylmethoxycarbonyl (Fmoc) amino acid blocking groups and separation of the polypeptide from the resin can be accomplished by acid treatment at low temperatures. The polypeptide-containing mixture can then be extracted, for example, with dimethyl ether, to remove non-peptide organic compounds, and the synthesized polypeptide can be extracted from the resin powder (e.g., with about 25% w / v acetic acid). Following synthesis of the polypeptide, further purification (e.g., using high performance liquid chromatography (HPLC)) can optionally be performed to eliminate any incomplete polypeptides or free amino acids. The synthesized polypeptide can be subjected to amino acid and / or HPLC analysis to verify identity. For other applications according to the present invention, it may be preferred to produce the polypeptide as part of a larger fusion protein (e.g., by the methods described herein or other genetic means) or as part of a larger conjugate (e.g., by physical or chemical conjugation, as known to those of ordinary skill in the art and described herein).
[0216] In any embodiment of the present invention, the chimeric or fusion protein of the present invention may include additional amino acid residues to promote expression in a recombinant expression system and / or to promote purification of the protein. Thus, the protein defined herein may include additional amino acids, such as one, two, three, four, or five amino acids in the N-terminal region. Typically, the additional amino acids will include an N-terminal methionine to promote expression in a recombinant expression system, although it will be understood that typically such N-terminal residues will be cleaved after translation of the protein. In certain embodiments, the N-terminal amino acid residues include at least a methionine and an alanine residue.
[0217] In addition, the chimeric or fusion protein according to the present invention may contain additional amino acids, such as one, two, three, four or five amino acids, in the N-terminal region or the C-terminal region, preferably to facilitate purification. It should be understood that such amino acid residues may facilitate the inclusion of purification tags (such as histidine tags, etc.) in the protein. When generating an untagged version of the protein, such residues may not be included.
[0218] The polypeptides of the present invention may also be modified with, conjugated to, or fused to another moiety to facilitate purification, or to increase the in vivo half-life of the polypeptide, or for use in immunoassays using methods known in the art. For example, the polypeptides of the present invention may be modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, and the like.
[0219] Nucleic Acids
[0220] Nucleic acid molecules encoding any one of the chimeric or fusion proteins or polypeptides of the present invention are also within the scope of the present invention. For example, nucleic acids can be used to prepare polypeptides of the present invention and as therapeutic agents. They can be applied to cells in culture or in vivo and can comprise secretion signals that instruct or promote secretion of the polypeptides of the present invention from cells. Expression vectors and host cells containing or comprising nucleic acids of the present invention are also within the scope of the present invention (described further below). Although the nucleic acids of the present invention can be referred to as "isolated", by definition, the polypeptides of the present invention are not wild-type polypeptides and therefore will not be encoded by naturally occurring nucleic acids. Therefore, although the polypeptides and nucleic acids of the present invention can be "purified", "substantially purified" or "isolated", "recombinant" or "synthetic", in order to distinguish them from naturally occurring substances, they do not need to be so.
[0221] An "isolated" nucleic acid molecule is one that has been identified and separated from at least one contaminant nucleic acid molecule typically associated with the natural source of the nucleic acid. An isolated nucleic acid molecule is not in the form or environment in which it is found in nature. Thus, an isolated nucleic acid molecule is distinguished from its nucleic acid molecule as found in natural cells. However, an isolated nucleic acid molecule includes nucleic acid molecules contained in cells that typically express Kgp, wherein, for example, the nucleic acid molecule is located in a chromosomal location that is different from the location in the natural cell.
[0222] The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably herein and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or their analogs. Non-limiting examples of polynucleotides include genes, gene fragments, messenger RNA (mRNA), cDNA, recombinant polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. The polynucleotides of the present invention can be provided in an isolated or purified form. A nucleic acid sequence that "encodes" a selected polypeptide is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by the start codon at the 5' (amino) end and the translation stop codon at the 3' (carboxyl) end. For the purposes of the present invention, such nucleic acid sequences may include, but are not limited to, cDNA from viral, prokaryotic, or eukaryotic mRNA, genomic sequences from viral or prokaryotic DNA or RNA, and even synthetic DNA sequences. A transcription termination sequence may be located at the 3' end of the coding sequence.
[0223] The polynucleotides of the present invention can be synthesized according to methods well known in the art, as described by way of example in Sambrook et al. (1989, Molecular Cloning—a laboratory manual; Cold Spring Harbor Press).
[0224] The polynucleotide molecules of the present invention can be provided in the form of an expression cassette, and the expression cassette comprises a control sequence operably connected to an insertion sequence, thereby allowing the polypeptide of the present invention to be expressed in vivo in the experimenter of the target. Conversely, these expression cassettes are generally provided in a carrier (for example, a plasmid or a recombinant viral vector) that is suitable for use as a reagent for nucleic acid immunization. This type of expression cassette can be directly applied to a host subject. Alternatively, a carrier comprising the polynucleotide of the present invention can be applied to a host subject. Preferably, genetic vectors are used to prepare and / or administer polynucleotides. Suitable vectors can be any vector that can carry sufficient genetic information and allow expression of the polypeptide of the present invention.
[0225] Thus, the present invention encompasses expression vectors comprising such polynucleotide sequences. Thus, the present invention provides a vector for preventing or treating an inflammatory disease or condition, the vector comprising a polynucleotide sequence encoding a polypeptide of the present invention and optionally one or more further polynucleotide sequences encoding a different polypeptide as defined herein.
[0226] In addition, it should be understood that the compositions and products of the present invention may include a mixture of polypeptides and polynucleotides. Therefore, the present invention provides a composition or product as defined herein, wherein any one of the polypeptides is replaced by a polynucleotide capable of expressing a polypeptide.
[0227] Expression vectors are conventional constructs in the field of molecular biology and may, for example, involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, such as, for example, polyadenylation signals, which may be necessary and positioned in the correct orientation to allow expression of the peptides of the present invention. Other suitable vectors will be apparent to those skilled in the art. As further examples in this regard, reference is made to Sambrook et al.
[0228] Thus, the polypeptides of the present invention can be provided by delivering such vectors to cells and allowing transcription from the vector. Preferably, the polynucleotides of the present invention or the polynucleotides used in the vectors of the present invention are operably linked to control sequences capable of providing expression of the coding sequence by the host cell, i.e., the vector is an expression vector.
[0229] "Operably linked" refers to an arrangement of elements in which the components so described are configured to perform their usual functions. Thus, a given regulatory sequence (such as a promoter) operably linked to a nucleic acid sequence is capable of affecting the expression of that sequence in the presence of appropriate enzymes. The promoter need not be adjacent to the sequence, as long as it serves to direct its expression. Thus, for example, an intervening, untranslated, but still transcribed, sequence can be present between the promoter sequence and the nucleic acid sequence, and the promoter sequence can still be considered "operably linked" to the coding sequence.
[0230] Various expression systems have been described in the art, and each expression system in the expression system is generally composed of a vector containing a gene or nucleotide sequence of interest that is operably connected to an expression control sequence. These control sequences include transcription promoter sequences and transcription initiation and termination sequences. The carrier of the present invention can be, for example, a plasmid, a virus or a phage vector, and the carrier is provided with a replication origin, a promoter optionally for expression of the polynucleotide and optionally a regulatory factor of the promoter. A "plasmid" is a carrier in the form of an extrachromosomal genetic element. The carrier can contain one or more selectable marker genes, such as the ampicillin resistance gene in a bacterial plasmid or the resistance gene of a fungal vector. The carrier can be used in vitro, for example, for producing DNA or RNA, or for transfection or transformation of a host cell, such as a mammalian host cell. The carrier can also be suitable for use in vivo, for example, to allow expression of a polypeptide in vivo.
[0231] A "promoter" is a nucleotide sequence that initiates and regulates transcription of a polynucleotide encoding a polypeptide. Promoters can include inducible promoters (wherein expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), repressible promoters (wherein expression of a polynucleotide sequence operably linked to the promoter is repressed by an analyte, cofactor, regulatory protein, etc.), and constitutive promoters. The terms "promoter" or "control element" are intended to encompass full-length promoter regions and functional (e.g., controlling transcription or translation) segments of these regions.
[0232] The polynucleotide, expression cassette or vector according to the present invention may further comprise a signal peptide sequence. The signal peptide sequence is typically inserted in an operably linked manner to a promoter so that the signal peptide is expressed and promotes secretion of the polypeptide encoded by the coding sequence, which is also operably linked to the promoter.
[0233] Typically, a signal peptide sequence encodes a peptide of 10 to 30 amino acids, such as 15 to 20 amino acids. Typically, the amino acids are primarily hydrophobic. Typically, the signal peptide targets the growing polypeptide chain carrying the signal peptide to the endoplasmic reticulum of the expressing cell. The signal peptide is cleaved in the endoplasmic reticulum, allowing the polypeptide to be secreted through the Golgi apparatus.
[0234] Immunogenicity and vaccine composition
[0235] The present invention further provides compositions comprising the chimeric or fusion proteins defined herein, and the use of such chimeric or fusion proteins in immunogenic or vaccine compositions for treating or preventing P. gingivalis infection.
[0236] As used herein, the term "vaccine composition" is defined as a composition used to elicit an immune response against an antigen (immunogen) within the composition to protect or treat an organism against disease.
[0237] As used herein, the terms "immunostimulatory composition," "vaccine composition," and "immunogenic composition" are often used interchangeably.
[0238] In addition to one or more peptides of the present invention as therapeutic or preventive active ingredients, the immunostimulatory composition or vaccine of the present invention may suitably comprise a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, buffer or stabilizer. Such carriers include, but are not limited to, saline, buffered saline, dextrose, liposomes, water, glycerol, polyethylene glycol, ethanol and combinations thereof.
[0239] The immunostimulatory composition or vaccine composition can be suitable for administration by any appropriate route, for example, by parenteral (including subcutaneous, intramuscular, intravenous or intradermal or by injection into cerebrospinal fluid), oral (including buccal or sublingual), nasal, topical (including buccal, sublingual or transdermal), vaginal or rectal routes. Such compositions can be prepared by any method known in the pharmaceutical field, for example, by mixing the peptide with a carrier or excipient under aseptic conditions. Typically, the vaccine composition is suitable for administration by subcutaneous, intramuscular, intravenous or intradermal routes, typically by injection. Alternatively, the vaccine composition can be suitable for oral or nasal administration.
[0240] Suitable immunostimulatory compositions or vaccine compositions for parenteral administration can be aqueous and non-aqueous sterile injection solutions, which can contain antioxidants, buffers, antibacterial agents, and solutes that make the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which can contain suspending agents and thickening agents. Excipients that can be used for injectable solutions include, for example, water, alcohol, polyols, glycerol, and vegetable oils. Compositions can be present in unit dose or multidose containers, such as sealed ampoules and vials, and can be stored under freeze-dried (lyophilized) conditions that only require the addition of a sterile liquid carrier, such as water for injection, immediately before use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
[0241] Immunostimulatory or vaccine compositions suitable for oral administration may be presented as discrete units, such as capsules or tablets or lozenges; as a powder or granules; as a solution, syrup or suspension (in an aqueous or non-aqueous liquid; or as an edible foam or paste; or as an emulsion).
[0242] Suitable excipients for tablets or hard gelatin capsules include lactose, corn starch or its derivatives, stearic acid or its salts. Suitable excipients for use with soft gelatin capsules include, for example, vegetable oils, waxes, fats, semi-solid or liquid polyols, etc.
[0243] For the preparation of solutions and syrups, excipients that may be used include, for example, water, polyols and sugars. For the preparation of suspensions, oils (eg, vegetable oils) may be used to provide oil-in-water or water-in-oil suspensions.
[0244] Immunostimulatory or vaccine compositions suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns, which is administered as a snuff, i.e., by rapid inhalation through the nasal passages from a powder container held close to the nose. Suitable compositions for administration as nasal sprays or nose drops, wherein the carrier is a liquid, may include aqueous or oily solutions of the active ingredient.
[0245] Compositions suitable for administration by inhalation comprise fine particle dusts or mists which can be generated by various types of metered dose pressurized aerosols, nebulizers or insufflators.
[0246] Immunostimulatory or vaccine compositions suitable for transdermal administration can be presented as discrete patches intended to remain in close contact with the epidermis of the recipient for extended periods of time. For example, the active ingredient can be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research. 3(6):318 (1986).
[0247] Compositions suitable for topical application can be formulated as ointments, creams, suspensions, lotions, powders, solutions (such as mouthwashes), pastes, gels, sprays, aerosols or oils. For the infection of eyes or other external tissues (such as oral cavity and skin), compositions can be used as topical ointments or creams. When formulated in ointments, active ingredients can be used together with paraffin ointment base or water miscible ointment base. Alternatively, active ingredients can be formulated in the cream together with oil-in-water cream base or water-in-oil base. Pharmaceutical compositions suitable for topical application to eyes can include eye drops, wherein the active ingredient is dissolved or suspended in a suitable carrier, especially in an aqueous solvent. Pharmaceutical compositions suitable for topical application in the oral cavity can include lozenges, pastilles and mouthwashes.
[0248] Immunostimulatory or vaccine compositions may contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, salts (the substances of the present invention themselves may be provided in the form of pharmaceutically acceptable salts), buffers, coating agents, or antioxidants.
[0249] In addition to the chimeric or fusion protein as defined herein, the vaccine composition of the invention may also contain one or more other prophylactically or therapeutically active agents.
[0250] The chimeric or fusion proteins used in the vaccine compositions of the present invention may be lyophilized or not.
[0251] In addition to the peptides as defined herein, the vaccine compositions of the present invention may also comprise a pharmaceutically acceptable adjuvant. An adjuvant is added to enhance the immunogenicity of the vaccine composition.
[0252] Suitable adjuvants for inclusion in the vaccine compositions are known in the art and include incomplete Freund's adjuvant, complete Freund's adjuvant, Freund's adjuvant with MDP (muramyl dipeptide), alum (aluminum hydroxide), alum plus Bordatella pertussis and immunostimulating complexes (ISCOMs, typically a matrix of Quil A containing viral proteins), QS-21, Detox-PC, MPL-SE, MoGM-CSF, TiterMax-G, CRL-1005, GERBU, TERamide, PSC97B, Adjumer, PG-026, GSK-I, GcMAF, B-alethine, MPC-026, Adjuvax, CpG ODN, Betafectin, and MF59.
[0253] The vaccine compositions of the present invention may also comprise or be co-administered with one or more co-stimulatory molecules.
[0254] The dosage of the vaccine composition of the present invention may vary within wide limits, depending, among other things, on the age and condition of the individual to be treated, and the physician will ultimately determine the appropriate dosage to use.
[0255] This dosage can be repeated at an appropriate frequency. For example, an initial dose of the vaccine can be administered, and then a booster administered at a later date.
[0256] For use to mammals (particularly people), it is expected that the daily dose of the active agent will be 1 μg / kg to 10 mg / kg body weight, typically about 10 μg / kg to 1 mg / kg body weight. In any case, the doctor will determine the actual dosage that is most suitable for the individual based on factors such as the age, body weight, sex and response of the individual. The above dosage is an example of a general situation. Of course, there can be situations in which higher or lower dosage is a matter of course, and this type of dosage range is within the scope of the present invention.
[0257] The vaccine compositions of the invention may be administered by any convenient route as described herein, such as intramuscularly, intravenously, by inhalation, intraperitoneally or orally or by injection into the cerebrospinal fluid.
[0258] The vaccine compositions of the present invention can be provided in unit dosage form, typically in a sealed container, and can be provided as part of a kit. Such kits typically (although not necessarily) include instructions for use. They can include a variety of such unit dosage forms.
[0259] Thus, in yet another aspect, the present invention provides a kit of parts comprising the vaccine composition of the present invention and one or more cytokines and / or adjuvants in a sealed container.
[0260] Methods for immunizing a subject using a chimeric or fusion protein of the subject
[0261] The present invention provides methods and compositions for treating, preventing, or minimizing the likelihood of infection with Porphyromonas gingivalis in an individual in need thereof, the methods comprising administering a fusion or chimeric protein of the present invention.
[0262] The present invention also provides methods and compositions for inducing a humoral immune response to Porphyromonas gingivalis in a subject. The humoral response may be for the purpose of obtaining protective / therapeutic anti-Porphyromonas gingivalis antibodies directly in the body of an individual in need of protection / therapy. Alternatively, the humoral response may be for the purpose of producing antibodies and then isolating the antibodies from the subject (or their eggs) so that the antibodies can then be directly administered to an individual in need of treatment / protection with the antibodies.
[0263] Thus, the present invention encompasses methods and compositions for preventing, minimizing the likelihood of, and / or reducing the severity and duration of a Porphyromonas gingivalis infection in a subject.
[0264] The present invention also provides a method for obtaining antibodies against Porphyromonas gingivalis, comprising administering a chimeric or fusion protein, composition, vaccine, or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal. Preferably, the method further comprises isolating the antibodies from the animal (e.g., from the animal's blood) or from the animal's eggs (e.g., in the case of IgY antibodies produced from chickens).
[0265] The present invention also provides an antibody preparation comprising antibodies against Porphyromonas gingivalis, wherein the antibody preparation is obtained by administering the chimeric or fusion protein, composition, vaccine or immunostimulatory composition of the present invention to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal, and isolating the antibodies from the animal or its eggs.
[0266] Antibodies against P. gingivalis can be used therapeutically to eliminate or reduce P. gingivalis infection, or prophylactically to prevent or reduce the severity of P. gingivalis infection. In further embodiments, the antibodies can be used as diagnostic or analytical reagents.
[0267] As used herein, the term "treatment" or "treating" a subject includes applying or administering a composition of the invention to a subject (or applying or administering a compound of the invention to cells or tissues from a subject) for the purpose of delaying, slowing, stabilizing, curing, healing, alleviating, relieving, altering, remedying, reducing worsening, improving, ameliorging, or affecting a disease or condition, a symptom of a disease or condition, or the risk (or susceptibility) of a disease or condition. The term "treat" refers to any indicator of successful treatment or improvement of an injury, pathology, or condition, including any objective or subjective parameter, such as alleviation; remission; reducing the rate of worsening; lessening the severity of the disease; stabilizing, reducing symptoms, or making an injury, pathology, or condition more tolerable for the subject; slowing the rate of worsening or decline; making the end stage of an worsening less debilitating; or improving the physical or mental well-being of the subject.
[0268] As used herein, "preventing" or "prevention" refers to at least reducing the likelihood of acquiring the risk (or susceptibility) of a disease or condition (i.e., preventing a subject who may be exposed to or susceptible to the disease but has not yet experienced or displayed symptoms of the disease from developing at least one of the clinical symptoms of the disease). Biological and physiological parameters for identifying such subjects are provided herein and are also well known to physicians.
[0269] The vaccine compositions of the present invention can be administered to subjects in greatest need, for example, in the context of human patients, children, or the elderly, or individuals at risk of exposure to P. gingivalis. The vaccine compositions of the present invention can also be administered to subjects suspected of having or diagnosed with a P. gingivalis infection.
[0270] The compositions and methods of the invention extend equally to use in both human and / or veterinary medicine, the production of diagnostic agents or the production of other therapeutic agents.
[0271] As used herein, the term "subject" should be understood to mean any animal, such as a mammal, including humans. Exemplary subjects include, but are not limited to, humans and non-human primates. For example, the subject can be a human. In another example, the subject can be a veterinary subject, such as a companion animal (cat, dog, guinea pig, etc.). As used herein, the terms "subject," "individual," and "patient" can be used interchangeably.
[0272] Those skilled in the art will be familiar with methods for determining successful vaccination / immunization with a chimeric or fusion protein or composition as described herein. For example, those skilled in the art will be familiar with methods for quantifying the antibodies produced following immunization and / or for quantifying the extent of the humoral (Th2) response induced following immunization.
[0273] Reagent test kit
[0274] In another embodiment, a kit or article of manufacture is provided, comprising one or more proteins, polypeptides or polynucleotides of the invention and / or the immunogenic composition as described above.
[0275] In yet another aspect, the present invention provides a kit of parts comprising the vaccine composition of the present invention and one or more adjuvants for separate, subsequent or simultaneous administration to a subject.
[0276] In other embodiments, a kit for the above-mentioned treatment or prevention application is provided, the kit comprising:
[0277] - a container containing a protein, polypeptide, polynucleotide or immunogenic composition of the invention;
[0278] - Label or package insert with instructions for use.
[0279] In any embodiment, the kit may contain one or more additional active principles or ingredients for eliciting an immune response to P. gingivalis in a subject.
[0280] The kit or "article of manufacture" may include a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, blister packs, and the like. The container may be formed from a variety of materials, such as glass or plastic. The container holds a therapeutic composition for effectively treating the condition and may have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper pierceable by a hypodermic needle). The label or package insert indicates that the therapeutic composition is used to treat the selected condition. In one embodiment, the label or package insert includes instructions for use and indicates that the therapeutic or preventive composition can be used to treat the inflammatory disease or condition described herein.
[0281] The kit may include (a) a therapeutic or prophylactic composition; and (b) a second container containing a second active principle or ingredient. The kit in this embodiment of the invention may further include a package insert indicating that the composition and other active ingredients can be used to treat the condition or prevent complications from the inflammatory disease or condition described herein. Alternatively or in addition, the kit may further include a second (or third) container comprising a pharmaceutically acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desired from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes.
[0282] In any embodiment, the therapeutic composition can be provided in the form of a disposable or reusable device comprising a container for holding the therapeutic, prophylactic or immunogenic composition. In one embodiment, the device is a syringe, an automatic injector or a nanopatch. The device can hold 0.1 to 2 mL of the therapeutic or immunogenic composition. The therapeutic or prophylactic composition can be provided in the device in a state ready for use or in a state requiring mixing, dissolution or resuspension or addition of additional components.
[0283] It should be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the various features mentioned or evident in the text or drawings. All these different combinations constitute various alternative aspects of the invention.
[0284] The following examples are described to more fully illustrate some embodiments of the present invention. However, the examples should not be construed as limiting the broad scope of the present invention. Those skilled in the art can easily design many variations and modifications of the principles disclosed herein without departing from the scope of the present invention.
[0285] Examples
[0286] The following examples describe a series of in vitro and in vivo studies related to the chimeric or fusion proteins of the present invention. Example 1 describes the materials and methods used in the studies described in Examples 2 and 3. Example 2 describes the results of the in vitro studies, and Example 3 describes the results of the in vivo studies.
[0287] Example 1: Materials and Methods
[0288] 1.1 Materials and methods for in vitro studies
[0289] Expression of recombinant proteins
[0290] Recombinant proteins (ie, various chimeric or fusion proteins as described herein) were expressed from pET28 vectors (or pDUET-1 for co-expression of rABM1+rABM2 from one vector) by induction with isopropyl β-D-thiogalactosidase (IPTG), essentially as follows.
[0291] Nucleic acids encoding different chimeras and components of chimeras, as well as fusion proteins (comprising the active site and adhesin domains), were generated by DNA splicing using Porphyromonas gingivalis W50 genomic DNA template and specially designed oligonucleotide primers by standard PCR or overlap extension ("SOEing") PCR. PCR fragments or SOEn PCR fragments were purified and ligated into the cloning vectors pGEMTeasy or pBHA and transformed into chemically competent Escherichia coli α-Gold cells (Bioline, New South Wales, Australia).
[0292] DNA sequences encoding individual additional KAS (i.e., active site) residues (with or without a "DSSG" amino acid linker region) were sequentially added to the recombinant chimera and Kgp adhesin domains, one at a time, essentially as follows: Restriction enzyme sites were introduced into the ends of the DNA inserts in the chimera and adhesin variant mother clones by PCR using oligonucleotide primers containing nucleotides specific for restriction enzymes. Synthetic DNA fragments encoding individual KAS sequences with corresponding restriction sequences were ligated to the ends of the DNA constructs from the mother clones, and the recombinant clones were purified. Subsequently, if a second or third additional KAS was added, additional restriction sequences were introduced into the ends of these clone inserts, and additional DNA fragments encoding KAS sequences with different restriction sites were ligated one at a time. Mother clone constructs with single, double, or quadruple linear KAS coding sequences were subjected to specific restriction digests, and the subfragments were then interchanged by ligation to generate a variety of variants (including those exemplified in Table 1).
[0293] Residues within ABM1 and ABM2 were mutated using the QuickChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) following the manufacturer's instructions.
[0294] The integrity of each insertion in the cloning vectors pGEMTeasy and pBH1 was confirmed by DNA sequencing (Applied Genetics and Diagnostics Facility, The University of Melbourne). The mutation was further verified by DNA sequencing of the entire insertion. The verified constructs were then subjected to restrictive digestion with a selection enzyme and inserted into the relevant pET expression vector in E. coli α selection chemically competent cells and subsequently cloned into the E. coli expression host BL21-CodonPlus (DE3) RIPL (Stratagene, Australia).
[0295] Study of the characteristics of chimeras that affect the solubility of recombinant proteins; small-scale
[0296] Use single colony transformant to inoculate 2mL of Luria Bertani (LB) broth containing 30μg / ml kanamycin (kanamycin) on orbital shaker at 37 ℃ overnight.Then use this inoculum to inoculate (1:100) 2ml of LB containing 30μg / ml kanamycin.Under 37 ℃, use 1mM IPTG to induce cell culture of OD600=0.6-1.0 for 2 hours.Cell culture is centrifuged and pellet is resuspended in 250μl PBS, and uses CPX750 ultrasonic processor (U.S. Cole Parmer Instrument Company (Cole Parmer Instrument Company, USA)) to carry out short ultrasonic treatment and centrifugation.
[0297] The solubility of recombinant protein is assessed by SDS-PAGE analysis of total lysate, soluble (supernatant) and insoluble (pellet) fraction.Under these initial pilot expression conditions, keep insoluble or show low-solubility recombinant protein and express under various relatively low temperatures (16 ℃ to 30 ℃) and low IPTG (0.01-0.5mM) conditions, to determine the optimum conditions that improve solubility.Under optimum conditions, all recombinant protein inductions are amplified (20-200ml) to test-large-scale solubility.For example, at different temperatures (30 ℃ for 5 hours or 16 ℃ for 16 hours), culture (200mL) is subjected to IPTG induction.
[0298] The cells were harvested and resuspended in lysis buffer (20 mM sodium phosphate, 500 mM NaCl, 0.5% v / v Triton X-100, 5 mg / ml DNAseI, 1X protease inhibitor cocktail, 1 mg / ml lysozyme, 10 mM imidazole, pH 8). The cell resuspension was incubated at 4° C. for 1 hour, and the clarified lysate was then centrifuged (8,000 ɡ, 30 minutes, 4° C.) to collect the supernatant (soluble) and pellet (insoluble) fractions and analyzed by SDS- and native-PAGE.
[0299] In-gel HIS staining of recombinant proteins
[0300] Following the manufacturer's instructions, the recombinant proteins subjected to SDS PAGE were stained using the Invision In-Gel His Staining Kit (Invitrogen). This staining is highly specific for His-tagged proteins. This procedure was used to identify N-terminal degradation of recombinant proteins, as all candidates contained a C-terminal His tag.
[0301] Large-scale purification of chimeras for animal model studies
[0302] The purification conditions for each recombinant protein are detailed in the following sections.
[0303] Protein expression and cell lysis
[0304] As previously described, all recombinant proteins identified for use as animal model vaccine candidates were expressed in E. coli BL21 (DE3) as recombinant C-terminal His-tagged fusion proteins or "tag-free" proteins. Cells were grown at 37°C in LB medium, TB medium, or modified M9 minimal medium supplemented with 50 μg / mL kanamycin. Cultures with an OD600 of 0.8-1.0 were induced with 0.4 mM IPTG at 37°C or 34°C for 2-4 hours, at 25°C for 12 hours, or at 16°C for 16-20 hours. After harvesting by centrifugation at 8000 g at 4° C., cells were lysed on ice for 1.5 hours in lysis buffer [0.35 mg / mL lysozyme, 40 μg / mL DNase I in TBS150 (50 mM Tris·Cl, 150 mM NaCl, pH 7.5)] plus 1% Triton X-100 and EDTA-free protease inhibitors (Complete ULTRATablets, Sigma-Aldrich), unless otherwise stated. Cell lysates were clarified by centrifugation at 23,500 g for 40 minutes at 4° C.
[0305] The initiator Met residue (aa 1) on all recombinant proteins shown in Table 1 (starting from the translation sequence MA) is removed in vivo by the E. coli N-terminal methionine processing enzyme (which cleaves methionine when the penultimate residue is a small residue). This was confirmed by mass spectrometry analysis of KDAK and KDAK variant recombinant proteins.
[0306] Purification of His-tagged proteins from the soluble fraction under native conditions
[0307] 1. Ni affinity chromatography
[0308] The cell lysate was clarified by centrifugation at 20,000 g at 4 ° C to remove cell debris. After filtering through a 0.22 μm filter, the lysate was loaded onto a HisTrap Ni affinity column (GE Healthcare) in loading buffer TBS300 (50 mM Tris Cl, 300 mM NaCl, pH 7.5) plus 10 mM imidazole and 1% Triton X-100. The column was washed thoroughly with loading buffer and then washed in 20 mM imidazole in TBS300. The bound protein was eluted with a 20-350 mM imidazole gradient in TBS300, and the absorbance was monitored at 280 nm. The peak fractions were analyzed by SDS- and / or native PAGE. The eluted target protein was concentrated using an Amicon filtration unit with a molecular weight cutoff of 3 kDa or 10 kDa depending on the protein size. The resulting protein solution was stored at -70 ° C for further purification.
[0309] 2. Anion Exchange Chromatography
[0310] The isoelectric points (pI) of all candidate proteins were predicted to be in the acidic range using the online analytical tool ProtParam – ExPASy (https: / / web.expasy.org / protparam / ), so anion exchange chromatography was applied for further purification when necessary. Briefly, the concentrated protein from Ni affinity purification was diluted into buffer A (50 mM Tris-Cl, 20 mM NaCl, pH 7.5) to reduce the ionic strength and then loaded onto an anion exchange HiTrap Q column (GE Healthcare) in buffer A. The protein was eluted with a 20 to 400 mM NaCl gradient in Tris buffer, monitoring absorbance at 280 nm. The target protein in the peak fraction was verified by SDS- and / or native PAGE and concentrated using an Amicon filtration unit with an appropriate molecular weight cutoff. The protein solution was stored at −70°C for further purification or buffer exchange using size exclusion chromatography or dialysis.
[0311] 3. Size Exclusion Chromatography
[0312] Size exclusion chromatography was performed on a HiLoad Superdex 200 or HiLoad Superdex 75 column (GE Healthcare) at 4°C. Proteins from further steps of Ni affinity purification or anion exchange chromatography were loaded into appropriate columns and eluted in TBS150 or TBS100 buffer (100 mM NaCl in 50 mM Tris.Cl, pH 7.5), monitoring the absorbance at 280 nm. The target protein in the peak fractions was verified by SDS- and / or native PAGE. In order to separate single oligomeric species, such as dimers, a second or further round of size exclusion purification was performed. The fractions containing the best protein purity were pooled and concentrated. In order to prepare a mixture of protein homomultimers, the target protein fractions were simply pooled and concentrated. Where necessary, protein identity was confirmed by determining intact protein molar mass by liquid chromatography-electrospray ionization spectrometry (LC-MS, Agilent) or sequence analysis by liquid chromatography-Orbitrap tandem mass spectrometry (LC-MS / MS, Agilent). Protein concentration was quantified by determining absorbance at 280 nm using the calculated extinction coefficient prior to submission for animal model experiments.
[0313] Purification of His-tagged proteins from inclusion bodies
[0314] 1. Under oxidative conditions
[0315] After cell lysis (as described for purification from soluble fraction), insoluble pellet was washed twice with TBS150. The protein expressed as inclusion body was dissolved 1 hour at room temperature on a rolling platform with 8M urea in TBS300 or 20mM NaPi, 500mM NaCl, pH 7.4 (PBS500). Protein extract was centrifuged and filtered by 0.22 μm filter unit under 20,000g, and then loaded into the HisTrap affinity column in the buffer TBSU (8M urea in TBS300 adds 20mM imidazoles) or PBSU (8M urea, 20mM NaPi, pH 7.8,500mM NaCl adds 20mM imidazoles) containing urea. Fully wash column with same 8M urea buffer. Further wash with PBSU at pH 6.5 and be applied to the column with protein being loaded in PBSU. The protein of the present invention is eluted from the resin by 500mM imidazoles in PBSU.In order to remove urea, the target protein is eluted with the gradient elution of 20-500mM imidazoles in PBSU.When using loose Ni-NTA resin (Thermofisher), in PBSU, urea extract is mixed with resin for 2 hours while stirring gently.After fully washing with PBSU (pH 7.8, and then pH 6.5), and with 500mM imidazoles in the same buffer solution, the protein of elution bond is eluted from resin.The protein of wash-out is progressively dialyzed into 6M, 4M and then 2M urea phosphate buffer in the dialysis tubing with a molecular weight cutoff of 3.5kDa (Australian Fei Shi Er Biotechnology Co., Ltd. (FisherBiotec, Australia)).Before submitting to the animal model experiment, the protein in 2M urea buffer is further dialyzed into saline, and maintained at 4 DEG C, or submitted to 2M urea buffer without further dialysing.
[0316] 2. Under reducing conditions
[0317] In the presence of 5mM TCEP, protein was extracted from inclusion bodies with 6M urea buffer and loaded onto a HisTrap column in the same buffer. After washing the column with 4M urea buffer containing 2M TCEP, the target protein was refolded on the column using a decreasing concentration gradient of urea from 4 to 0M in the presence of 2M TCEP. The protein was then eluted with an increasing concentration gradient of imidazole from 20-350mM in TBS300 plus 2mM TCEP. The eluted protein was then concentrated in a reducing buffer (2mM TCEP in TBS150) to perform size exclusion chromatography, following the same procedure described in the section on purifying protein dimers or multimers from the soluble fraction under non-denaturing conditions. After SDS- and native PAGE, mass spectrometry, and quantitative analysis, the samples were stored in a reducing buffer at -70°C or submitted for animal model experiments.
[0318] Purification of His-tagged proteins from the soluble fraction under oxidative and denaturing conditions
[0319] The cell lysate was clarified by centrifugation at 20,000 g to remove debris and insoluble material, and then the lysate was immediately denatured by adding urea solution in PBS 500 to a final concentration of 8 M and stirred at room temperature for 1 hour. The resulting lysate was then centrifuged at 20,000 g for 40 minutes at room temperature. The target protein was purified using a HisTrap Ni affinity column or loose Ni-NTA resin according to the same method as described in the section on purification from inclusion bodies under oxidative conditions above. The purified antigen was stored at 4°C in saline before submission for animal model experiments.
[0320] Purification of tag-free candidates from the soluble fraction
[0321] Anion exchange chromatography This is the first chromatographic step in the purification of tag-free proteins. Like their His-tagged counterparts, the pI of the tag-free candidate was predicted to be in the acidic range using the online analytical tool ProtParam – ExPASy (https: / / web.expasy.org / protparam / ). Therefore, two rounds of anion exchange chromatography were applied. In the first round, clarified cell lysate was filtered through a 0.22 μm filter disk and loaded onto an anion exchange HiTrap Q column (GE Healthcare) in buffer AA (20 mM NaPi, pH 6.5, supplemented with 0.05x protease inhibitor cocktail). After washing with 10 column volumes of buffer AA, bound proteins were eluted with a 0–100% NaCl gradient in buffer BA (1 M NaCl in 20 mM NaPi, pH 6.5), and absorbance at 280 nm was monitored. Peak fractions were verified for target protein using SDS- and / or native PAGE. In the second round, the best fractions from the anion exchange step of the first round were pooled and diluted 6-fold with buffer AA and then reloaded onto an anion exchange HiTrap Q column (GE Healthcare) in the same buffer. The bound protein was eluted with a 0-50% NaCl gradient in buffer BA, monitoring the absorbance at 280 nm. The target protein in the peak fraction was verified by SDS- and / or native PAGE, and the best fraction was concentrated using an Amicon filtration unit with a molecular weight cutoff of 10 kDa. The protein solution was stored at -20°C for further purification by size exclusion chromatography.
[0322] First round of size exclusion chromatographySize exclusion chromatography was performed on a HiLoad Superdex 200 column (GE Healthcare) at room temperature. The purified protein from anion exchange chromatography was loaded onto a size exclusion column and eluted in AS buffer (1 M (NH4)2SO4, 50 mM NaPi, pH 7.0, supplemented with 0.05x protease inhibitor cocktail), monitoring absorbance at 280 nm. The target protein in the peak fraction was verified by SDS- and / or native PAGE. The fractions with the best protein purity were pooled for further purification by hydrophobic interaction chromatography.
[0323] Hydrophobic interaction chromatography The pooled fractions of the target protein in buffer AS from the first round of size exclusion chromatography were filtered through a 0.22 μm membrane and loaded onto a HiTrap Phenyl HP column pre-equilibrated in buffer AH (1 M (NH4)2SO4, 50 mM NaPi, pH 7) at 4°C. The bound protein was eluted with a gradient of decreasing ionic strength from 800 mM to 200 mM (NH4)2SO4 in buffer BH (50 mM NaPi, pH 7), monitoring the absorbance at 280 nm. The target protein in the peak fractions was verified by SDS- and / or native PAGE and the best fractions were pooled and concentrated using an Amicon filtration unit for the next purification or buffer exchange step of the second round of size exclusion chromatography.
[0324] Second round of size exclusion chromatography The concentrated sample from the purification step with hydrophobic interaction is loaded into the size exclusion column used in the first round size exclusion chromatography and eluted in the buffer of BTS (20mM Bis-Tris, 150mM NaCl, pH 6.5). Analyze the peak fraction with SDS-and / or native PAGE. The fractions of optimal purity are collected and concentrated. After identifying and quantifying with liquid chromatography-electrospray ionization mass spectrometry (LC-MS, Agilent), the antigen is divided into equal parts and stored at-80 ℃ for future use.
[0325] Protein identification and quantification of label-free candidates
[0326] In addition to SDS- or native PAGE verification, protein identity was confirmed by determining the intact protein molar mass using LC-MS or by sequence analysis using liquid chromatography-Orbitrap tandem mass spectrometry (LC-MS / MS, Agilent). Protein concentration was quantified by determining the absorbance at 280 nm using the calculated extinction coefficient (Table 3). In cases where buffer exchange was required before submission for animal model experiments, a Superdex 200 size exclusion column (GE Healthcare) or a ZebaTM Spin Desalting Column (ThermoFisher Scientific).
[0327] 1.2 Materials and methods for in vivo studies
[0328] Bacterial Culture in the Mouse Model of Periodontitis
[0329] Porphyromonas gingivalis strain; W50 (serotype C) was obtained from the culture collection of the Oral Health Cooperative Research Centre, The Melbourne Dental School, University of Melbourne, Australia. Porphyromonas gingivalis W50 was grown on horse blood agar (HBA) (20 g / L HBA; Oxoid Ltd., Hampshire, UK) supplemented with 10% v / v lysed horse blood (37° C.) in an anaerobic N atmosphere containing 5% CO in a MK3 anaerobic workstation (Don Whitley Scientific Ltd., Adelaide, Australia). The colony was inoculated into a starter culture containing 20 mL of sterile brain heart infusion (37 g / L BHI; Oxoid, Hampshire, England) medium supplemented with 5 mg / L hemin and 0.5 mg / L cysteine [McKee et al. (1986) Infect Immun 52:349-355] and incubated anaerobically (24 hours, 37°C). The absorbance of the batch culture was monitored at OD650 nm using a spectrophotometer (Model 295E, Perkin-Elmer, Germany). Bacterial cells were harvested during late exponential growth by centrifugation (7,000 g, 20 minutes, 4°C). Bacterial purity was routinely confirmed by Gram staining [Slots (1982). Host-Parasite Interaction in Periodontal. Genco, RJ and Merganhagan, SE (eds.). Washington DC: American Society for Microbiology. pp. 27-45].
[0330] Preparation of heat-killed bacteria
[0331] Porphyromonas gingivalis W50 culture (6,500g, 4 ° C) was collected, washed once with phosphate buffered saline (PBS) (0.01MNa2HPO4, 1.5mM KH2PO4 and 0.15M NaCl, pH 7.4), and then pelleted by centrifugation (7,000g, 20 minutes, 4 ° C). The bacterial cells were resuspended in PBS and heated to 65 ° C for 15 minutes. The suspension was centrifuged (7,000g, 20 minutes, 4 ° C) and resuspended in sterile PBS, and this was repeated once. After the second wash, the supernatant was discarded and the cell pellet was resuspended in sterile PBS to obtain 2×10 10 Cell densities were determined at 10 cells / mL, and protein concentrations were determined using Biorad Protein Assay Dye Reagent Concentrate (Life Science, NSW, Australia).
[0332] Mouse periodontitis model
[0333] The mouse periodontitis experiment was modified from the model of Baker et al. (1994). Arch Oral Biol 39:1035-1040 and performed as previously described by O'Brien-Simpson et al. (2005 J Immunol 175:3980-3989). On day 0, mice (female BALB / c; 6-8 weeks old, 10 mice / group) were intraorally inoculated with four doses of P. gingivalis W50 [1×10 10 gingivalis W50 cells suspended in 20 μL PG buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM MgSO4 and 14.3 mM mercaptoethanol, pH 7.4) containing 2% w / v carboxymethylcellulose (CMC, Sigma, New South Wales, Australia)] were administered at two-day intervals. The inoculum was prepared anaerobically and then immediately applied to the gingival margin of the maxillary molars. The number of viable bacteria in each inoculum was verified by flow cytometry and CFU counts on blood agar. The animal groups consisted of: an orally inoculated P. gingivalis W50 group (infected control), a non-bacterial inoculated control group and an immunized group. For the therapeutic vaccination periodontitis model ( Figure 1), mice were immunized intraperitoneally 19 days after the first oral vaccination with 50 μg of the vaccine candidate in saline / alum (alveolar gel; 2% aluminum hydroxide wet gel suspension; Invivogen). On day 40, mice received a second immunization (50 μg in saline / alum) via the subcutaneous route. On day 62, mice were exsanguinated by cardiac puncture and sacrificed. The maxilla was removed and split in half along the midline, with 10 halves used to determine alveolar bone loss. Sera were used to determine antibody profiles using ELISA.
[0334] Measurement of alveolar bone loss in the mouse maxilla
[0335] The maxilla to be examined for bone loss was boiled in deionized water (1 minute), mechanically fleshed and immersed in 2% w / v potassium hydroxide (16 hours, 25°C). The maxilla was washed twice with deionized water (25°C), dried (1 hour, 37°C) and stained with 0.5% w / v methylene blue in water. Digital images of the buccal side of the maxilla were taken with an Olympus DP12 digital camera mounted on a dissecting microscope to assess horizontal bone loss using OLYSIA BioReport software version 3.2 (Olympus Australia Pty Ltd, New South Wales, Australia). The maxilla was oriented so that the buccal and lingual molar cusps overlapped. Images were captured in frames in micrometers so that measurements could be standardized for each image. Horizontal bone loss is defined as bone loss that occurs in a horizontal plane perpendicular to the alveolar bone ridge, resulting in a decrease in ridge height. The visible area from the cementoenamel junction (CEJ) to the alveolar bone crest (ABC) of each molar was measured using OLYSIA BioReport software version 3.2. 2 The total visible CEJ-ABC area is given in units of 4. 2 The total visible CEJ-ABC area (in mm) was calculated by subtracting the total visible CEJ-ABC area of the non-vaccinated (NC) group from the total visible CEJ-ABC area of each experimental group. Alveolar bone loss measurements were determined twice in a randomized and blinded protocol. Data are presented as mean + / - standard deviation (in mm 2 The data were expressed as % (unit) and analyzed using one-way ANOVA and Dunnett's T3 post hoc test.
[0336] Pre-screening of vaccine candidates by enzyme-linked immunosorbent assay (ELISA)
[0337] Vaccine candidates were pre-screened using several monoclonal antibodies against Porphyromonas gingivalis to determine whether the major domains and epitopes present in the vaccine constructs were accessible to antibodies, thereby generating an antibody response in vivo. The antigens to be screened were coated onto flat-bottomed polyethylene microtiter plates (Microtiter; Dynatech Laboratories, McLean, VA, US) in 0.1M PBS (pH 7.4) for 16 hours at 4°C. In these experiments, the following antibody dilutions were used: 1 / 4000 dilution of goat anti-mouse; IgG (M8642) antibody (Sigma, New South Wales, Australia). ELISA experiments were developed using a 1 / 4000 dilution of horseradish peroxidase-conjugated pig anti-goat IgG antibody (M5420; Sigma, New South Wales, Australia).
[0338] Determination of antibody subclasses in serum using ELISA
[0339] As described by Pathirana et al. (2007). Infection and Immunity 75: 1436-1442, ELISA was performed to assess subclass antibodies in serum using HK W50 cells, domain subunits, or epitope solutions (1 μg / mL) in 0.1 M PBS (pH 7.4) to coat the wells of flat-bottom polyethylene microtiter plates (Microtiter; Dyna Scientific, McLean, VA, USA) (16 hours, 4°C). In these experiments, the following antibody dilutions were used: 1 / 4000 dilution of goat anti-mouse; IgG (M8642), IgG1 (M8770), IgG2a (M4434) antibodies (Sigma, New South Wales, Australia). A 1 / 4000 dilution of horseradish peroxidase-conjugated porcine anti-goat IgG antibody (M5420; Sigma, New South Wales, Australia) was used to develop the ELISA assay. For epitope ELISA, biotinylated peptides were bound to pre-blocked streptavidin-coated flat-bottom plates (Pierce; Thermo Fisher Scientific) at 10 μg / mL. After incubation with serum, ELISA was developed using 1 / 4000 goat anti-mouse IgG and 1 / 4000 horseradish peroxidase-conjugated porcine anti-goat IgG antibodies. All optical density measurements were performed on a Wallac VICTOR3 1420 Multilabel counter (PerkinElmer) at 405 nm.
[0340] Example 2: Results of in vitro studies
[0341] Effects of chimera components on the solubility of recombinant proteins
[0342] A previously reported chimera (in WO 2010 / 022463) consists of a KAS (K) peptide conjugated to an N-terminally truncated DUF2436 domain (Dc), an adhesin domain comprising ABMs213 (A), and a C-terminally truncated CAD domain (a truncated K1 domain, referred to as K1n). This chimera is referred to as "KDcAK1n" (SEQ ID NO: 35) and may also be referred to herein as the "original chimera" or "chimera" in contrast to the chimeric and fusion proteins of the present invention. The KDcAK1n protein is produced as inclusion bodies in E. coli and has poor solubility and stability.
[0343] The truncated DUF and K1 domains of the A1 adhesin fragment represent how the Kgp polyprotein undergoes native proteolytic processing and assembly on the P. gingivalis cell surface during infection. Therefore, the truncated DUF and K1 domains are obvious candidates for inclusion in vaccines to generate an immune response to gingipains.
[0344] Numerous attempts were made to generate soluble KDcAK1n. Variations in growth medium, growth conditions, IPTG concentration, E. coli expression strain, induction temperature, cell growth phase during induction, addition of growth stabilizers, lysis buffer, and protein storage buffer were systematically investigated and extensively tested. Enhanced expression of soluble recombinant protein was observed in small-scale expression under low temperature and IPTG induction. At small scale, KDcAK1n produced approximately 30–50% of total recombinant protein expression as soluble protein. However, soluble recombinant production could not be scaled up to cultures larger than 10 ml, resulting in the formation of inclusion bodies in any scale-up attempt.
[0345] Effect of K1 domain on solubility
[0346] All intact DUF, ABM213, ABM21 and DUF-ABM213 domains of the Kgp polyprotein were expressed as highly soluble and stable recombinant proteins. However, the intact K1 domain alone was insoluble and expressed only as inclusion bodies (IBs).
[0347] Expression of the KAS motif conjugated to the ABM213 domain (ie, "KA") or to both the DUF domain and the ABM213 domain (ie, "KDA") resulted in highly soluble, stable recombinant proteins.
[0348] However, if Figure 2 As shown, addition of a C-terminally truncated K1 domain (ie, K1n fragment) or the complete K1 domain to recombinant KA or KDA (KAK1 or KDAK1) resulted in decreased solubility.
[0349] Both KDAK1n (SEQ ID NO: 36) and KDAK1 (SEQ ID NO: 37) proteins (i.e., comprising the K domain, the adhesin domain comprising DUF2436 and ABM, and either a truncated or full-length CAD domain) require more fastidious growth conditions to achieve soluble expression, with levels significantly lower than KDA (i.e., the same protein except for the truncated or full-length CAD).
[0350] Combined with the results of K1 domain expression, it is clear that the K1 (CAD) domain is the cause of the poor solubility of chimera-based reconstitution.
[0351] Effect of DUF domain on protein solubility
[0352] Truncation of the DUF domain in the chimeric protein construct resulted in abrogation of soluble protein expression. This result suggests that an intact DUF domain containing the additional 38 N-terminal residues is desirable for optimizing soluble expression and efficient stabilization of recombinant proteins.
[0353] Therefore, a construct was created to express a chimeric variant with an expanded Dc domain (a chimera with Dc extended by 38 N-terminal residues). This recombinant was named KDAK1n, and the results showed that the chimera with an intact DUF domain had significantly improved solubility. Large-scale expression of KDAK1n at 30°C with 0.2-0.5mM IPTG resulted in good yields of soluble recombinant protein.
[0354] Effects of K1 and full-length DUF domains on solubility
[0355] However, despite this scale of soluble protein expression, the inclusion of K1n / K1 in KDAK1n / KDAK1 does appear to be more problematic to prepare than KDA variants lacking K1n / K1, and thus these K1-involving variants may be less desirable for scale-up and commercial development.
[0356] The summary is as follows:
[0357] ● Full-length DUF domain is desirable for solubility of recombinant variants ( Figure 2 A)
[0358] • The K1 domain (whether full-length or truncated) is largely responsible for the aggregation and insolubility of the variants.
[0359] In the absence of the full-length DUF domain (ie, DUFc), variants containing K1 and K1n are completely insoluble ( Figure 2 A).
[0360] In the presence of the full-length DUF domain, very low solubility of the K1- and K1n-containing variants was evident under very mild induction conditions. However, this solubility was very low, with approximately 80–90% of all recombinant protein expressed as inclusion bodies.
[0361] Analysis of native PAGE gels of medium-scale purifications of soluble recombinant KDAK1 revealed disordered aggregation of the recombinants (i.e., the KDA variants were not a neat, uniform ladder). Small-scale purifications of these variants using mini-nickle spin columns (at low protein concentrations) did not induce similar aggregation, however, small-scale purifications of truncated DUF variants also revealed that the characteristic laddering of the protein on native PAGE was not uniform, indicating disordered aggregation.
[0362] Variants containing the K1 and K1n domains showed an increased tendency to aggregate at higher concentrations and after freeze-thaw of purified samples. The K1 domain is responsible for this instability. However, all variants lacking either K1 or K1n were very stable upon freeze-thaw and at higher concentrations (e.g., approximately 30 mg / ml).
[0363] Variants containing either full-length or truncated K1 domains were very insoluble, and the low levels of soluble recombinant protein produced after purification were prone to instability and aggregation. It was not possible to efficiently scale up soluble K1-containing variants.
[0364] Therefore, extending the DUF to full length and / or removing the K1 (or K1n) domain (preferably both) is important for the solubility and stability of the recombinant protein.
[0365] Active site (KAS) motif
[0366] Additional KAS motifs were engineered into the recombinant chimeric variants to determine whether this would affect immunogenicity. A single KAS or two consecutive KAS residues were added to the N-terminus or both ends of the variant. Additionally, a linear sequence of four KAS residues containing a DSSG linker sequence between each KAS motif was added to the N-terminus of the selected variant.
[0367] Purification curves and His-stained gel analysis of the recombinant protein revealed that the additional KAS residues caused some instability and degradation of the recombinant protein. The 4x linear KAS variant showed the greatest degradation and instability, suggesting that proteolytic processing occurred within the additional KAS sequence. Subsequent removal of the DSSG linker between adjacent KAS sequences did not improve stability.
[0368] It was concluded that when multiple consecutive KAS sequences were expressed in a linear sequence, these variants were susceptible to proteolytic processing. Soluble variants with a single KAS at one or both termini were relatively stable and less susceptible to degradation and reduced purification yield.
[0369] Large-scale protein yield and stability
[0370] Most recombinant proteins expressed as soluble proteins and purified under native conditions had relatively high yields of their final products (>10 mg / L culture and over 20 mg / L culture).
[0371] When purified from inclusion bodies or from soluble fractions under conditions intended to denature them (e.g., urea), the yields of these same recombinant proteins were much lower (2.1-3.6 mg / L culture). It should be noted that denatured proteins have low binding affinity to Ni affinity resins under denaturing conditions and low solubility when ultimately equilibrated in non-denaturing buffer. In addition, the variants purified from their denatured forms were unstable in non-buffered saline, regardless of whether the protein was initially expressed as a soluble protein or an insoluble form, and whether it was purified using pre-packed columns or loose Ni-NTA resins. These results suggest that it may be desirable to reduce or avoid the use of denaturants where such agents are not required.
[0372] Low expression temperatures of 16°C have been shown to effectively improve the soluble expression of poorly soluble proteins such as KDAK1 (SEQ ID NO: 37). However, during anion exchange purification, enrichment in low ionic strength buffers on the column significantly reduced the yield due to aggregation or precipitation on the column, even at a low temperature of 4°C. For these proteins, purification that bypassed the anion exchange step produced higher yields; for example, the yield of KDAK1 was doubled when produced in this manner. KDAK1n (SEQ ID NO: 36) was also found to be expressed as a soluble protein, but it appeared unstable in solution during subsequent purification, with a yield of only 2.3 mg / L of culture.
[0373] Given that K1 is insoluble and the addition of K1 or K1n to KDA or DA reduces the solubility of recombinant variants in large-scale purification, as described above, the K1 region may be responsible for the instability of K1-containing chimeric variants, and therefore exclusion of K1 is preferred if the domain is not required for protection.
[0374] Although His staining of the gel confirmed degradation in regions containing multiple KAS (K) residues, no negative impact of Ni affinity chromatography on yield was observed. For example, the protective antigens KKDAK1nKK (SEQ ID NO: 40) and KKDAKK (SEQ ID NO: 34) had over 90% of the expected full-length protein species in their final products, with yields ranging from 12-21 mg / L culture.
[0375] Reducing conditions were found to be beneficial for the extraction of insoluble KDcAK1n from inclusion bodies using urea. Higher concentrations of urea were required under non-reducing conditions than under reducing conditions.
[0376] When the proteins were expressed under the same conditions, the C-terminal His tag had no significant effect on protein production and solubility.
[0377] In the purification of the tag-free candidates, although anion exchange chromatography enriched the target protein, this step was unable to effectively separate the target protein from the E. coli host due to the tight binding affinity to the resin, as most E. coli proteins are acidic in the pI range of 4-7, many of which are close to the pI of the target protein. Interestingly, however, size exclusion chromatography with 1 M (NH4)2SO4 buffer at room temperature appeared to be the key step and provided a method for efficiently separating the target protein from the E. coli target protein. After further purification by hydrophobic interaction and a second round of size exclusion chromatography, both lead tag-free candidates were purified to 99% purity with high homogeneity, as demonstrated by SDS- / native PAGE and SEC-MALS analysis.
[0378] Table 2: Summary of recombinant Kgp chimeras and fragments expressed in E. coli
[0379]
[0380]
[0381] Example 3: Animal Studies
[0382] Porphyromonas gingivalis prevents bone loss in a mouse model of periodontitis
[0383] 1. Experiment 1
[0384] Antigens tested: KDcAK1n 50 μg; KDcAK1n 0.5 μg; KDA 50 μg; KDA 0.5 μg; KDAK1 50 μg; KDAK1 0.5 μg. All antigens were absorbed onto alum in PBS (pH 7.4).
[0385] KDcAK1n: From inclusion bodies, batch purification was performed using Ni-NTA resin followed by dialysis into 2 M urea in PBS under non-reducing conditions.
[0386] KDA and KDAK1: From the soluble fraction, Ni affinity (prepacked column) and anion exchange chromatography with gradient elution under non-reducing conditions followed by dialysis into PBS.
[0387] Porphyromonas gingivalis-induced alveolar bone loss in the mouse maxilla
[0388] KDcAK1n and KDA protect against bone loss in animal models. KDcAK1n protected against bone loss at both concentrations tested, while KDA only protected at 50 μg ( Figure 3 ).
[0389] Antibody response
[0390] Serum antibody subclass responses of mice immunized in the periodontitis model were determined by ELISA. Antisera were used to detect heat-inactivated P. gingivalis strain W50 as the adsorbed antigen. Antibody responses were expressed as the obtained ELISA titer minus three times the background level, where each titer represents the mean ± sd of 10 individual mice ( Figure 4 ). KDcAK1n(in Figure 4 Total IgG and IgG1 responses to whole cells of P. gingivalis were strongest with KDA (referred to as "chimera" in
[0014] ), followed by KDAK1. At 50 μg, there were no significant differences in IgG and IgG1 antibody responses between the antigens tested.
[0391] 2. Experiment 2
[0392] Antigens tested: KDcAK1n 50 μg; KDcAK1n 0.5 μg; KDA 50 μg; KDA 0.5 μg; KDAK1 50 μg; KDAK1 0.5 μg. All antigens were adsorbed onto alum in saline (pH 7.4).
[0393] The antigen was purified in the same manner as in Experiment 1.
[0394] Porphyromonas gingivalis-induced alveolar bone loss in the mouse maxilla
[0395] This experiment examined the same antigen as in Experiment 1; however, it was adsorbed onto the alum using saline rather than PBS. The bone loss results mirrored those in Experiment 1 and were Figure 3 (data not shown), in which only KDcAK1n and KDA showed protection, indicating that the use of PBS or saline for alum preparation had no effect on the experimental results.
[0396] Antibody response
[0397] All antigens tested induced similar total IgG and IgG1 responses against whole-cell P. gingivalis. KDA and KDAK1 induced stronger IgG2a responses compared to KDcAK1n (not shown).
[0398] 3. Experiment 3
[0399] Antigens tested: KKDA1nKK; KDAK1n; KKDAKK.
[0400] All antigens were purified from the soluble fraction using Ni affinity column, anion exchange and gel filtration chromatography under non-reducing conditions.
[0401] alum absorption
[0402] The ability of the 2% hydrogel to absorb antigen was tested by incubating the antigen with alum at 4°C for 60 minutes with gentle mixing. The alum was pelleted, and a Bradford protein assay was then performed on the antigen before and after alum adsorption. The percentage of all antigens bound to the alum ranged from 91.7% to 99.3%. SDS-PAGE gels were also run on samples before and after alum adsorption, and the results were consistent with the Bradford protein assay.
[0403] Prescreening vaccine candidates with mAbs targeting Porphyromonas gingivalis epitopes
[0404] All vaccine candidates were able to bind to KAS2, ABM3, and EP1 mAbs, with large titration curves visible compared to the negative control muBM4 mAb. KKDA1nKK, KDAK1n, and KKDAKK did not bind to the ABM2 mAb, indicating that the epitope recognized by this mAb is inaccessible in these constructs (not shown).
[0405] Porphyromonas gingivalis-induced alveolar bone loss in the mouse maxilla
[0406] KKDAK1nKK and KKDAKK protect against Porphyromonas gingivalis-induced bone loss ( Figure 5 ).
[0407] Antibody response
[0408] Serum antibody subclass responses in mice immunized in a periodontitis model were assessed by ELISA. Antisera were used to probe heat-killed P. gingivalis strain W50 as an adsorbed antigen. All antigens tested generated varying degrees of IgG responses. Protective KKDAK1nKK and KKDAKK induced robust total IgG and IgG1 responses against heat-killed P. gingivalis.
[0409] Pooled serum samples were used to probe for P. gingivalis domains adsorbed onto ELISA plates. All antigens generated total IgG responses to ABM21 (multimers and dimers) and ABM213 (multimers and dimers) to varying degrees. IgG responses to DUF2436 were only evident in antigens containing the complete DUF domain (KKDAK1nKK, KDAK1n, and KKDAKK). Pooled serum samples were also used to probe for P. gingivalis epitope peptides, and although there was a clear trend toward high KAS titers in protective antisera, no clear pattern between protection and non-protection was observed.
[0410] 4. Experiment 4
[0411] Antigen tested
[0412] All antigens were purified using Ni affinity chromatography under non-reducing conditions followed by dialysis into saline.
[0413] KDcAK1n - from inclusion bodies, using urea and purified affinity column (IB, urea, AC); KDA - from the soluble fraction and purified affinity column (S, AC); KDA - from the soluble fraction, using urea and purified affinity column (S, urea, AC); KDA - from the soluble fraction, using urea and purified affinity column (S, urea, AC); KDA - from the soluble fraction, using urea and a batch purification method (S, urea, batch); KDAK1 - from the soluble fraction, using urea and purified affinity column (S, urea, AC); KDAK1 - from inclusion bodies, using urea and purified affinity column (IB, urea, AC); KDAK1 - from inclusion bodies, using urea and a batch purification method (IB, urea, batch).
[0414] Vaccine candidates were prescreened with mAbs directed against P. gingivalis epitopes.
[0415] All candidates were able to bind to KAS2, ABM3, and EP1 mAbs, with large titration curves visible compared to the negative control muBM4 mAb. None of the antigens bound to the ABM2 mAb, indicating that the epitope recognized by this mAb is inaccessible in these constructs (not shown).
[0416] Porphyromonas gingivalis-induced alveolar bone loss in the mouse maxilla
[0417] KDcAK1n(IB, urea, AC), KDA(S, AC), KDAK1(S, urea, AC), KDAK1(IB, urea, AC), KDAK1(IB, urea, batched), and KDA(S, urea, batched) showed significant protection against bone loss, with KDcAK1n(IB, urea, AC), KDA(S, AC), and KDAK1(IB, urea, batched) providing the best protection. It should be noted that the significant protection observed with KDA(S, AC) was lost when denatured with urea (e.g., KDA(S, urea, AC)). Figure 6 ).
[0418] Notably, unfractionated affinity-purified antigens provided protection against bone loss, with good protection observed with affinity-purified soluble KDA, but this protection was partially lost upon treatment with urea under oxidative conditions, which promotes disulfide cross-linking of the denatured D and A domains. These results again suggest that urea should be avoided and that the preparation of soluble, folded domains is preferred.
[0419] 5. Experiment 5
[0420] Antigen tested
[0421] All antigens were purified using Ni affinity chromatography under non-reducing conditions followed by dialysis into saline. Antigens tested were: KDcAK1n - from inclusion bodies using urea and purified on affinity columns (IB, urea, AC); KDAK1nK, KDAK, KKDAKK, KKDAK1nKK.
[0422] Porphyromonas gingivalis-induced alveolar bone loss in the mouse maxilla
[0423] All antigens tested protected against P. gingivalis-induced bone loss. ( Figure 7 ).
[0424] Summary and discussion of the results presented in Examples 2 and 3
[0425] The work described in this report compared the production and efficacy of various vaccine candidates to identify components of a chimeric vaccine that would facilitate ease of production (e.g., components that aid in improving solubility and stability) and would be most effective in eliciting an immune response to P. gingivalis and / or reducing P. gingivalis-induced alveolar bone loss.
[0426] Although effective in preventing periodontal bone loss in an animal periodontitis model, the prior art vaccine KDcAK1n is expressed by Escherichia coli as inclusion bodies and exhibits variable solubility and stability.
[0427] KDcAK1n is based on the fusion of the active site sequence (KAS or K) of the Lys-specific gingipain Kgp with the processed adhesin fragment (A1) of the Kgp polyprotein. It is now clear from structural analysis of the Kgp polyprotein domain that the A1 adhesin fragment found on the cell surface consists of three discrete structural domains: the DUF domain (D), the ABM domain (A), and the K1 domain (K1). The processing of the Kgp polyprotein on the surface of Porphyromonas gingivalis to release the protease catalytic domain and adhesin involves a 38-amino acid truncation of the N-terminal DUF domain. However, adding these additional N-terminal 38 residues to the construct to generate the full DUF domain rather than the truncated domain (Dc) resulted in highly soluble recombinant proteins (e.g., DUF2436, KDA, and KKDAKK).
[0428] Based on cell surface processing of the Kgp polyprotein to generate the A1 adhesin fragment, KDcAK1n also contains a C-terminally truncated K1 domain (K1n). Adding the complete K1 domain with the deleted C-terminal sequence to K1n did not improve solubility, as the protein was still expressed primarily as inclusion bodies in E. coli. Since most constructs with partial or complete K1 domains exhibited some solubility issues, it was concluded that an intact DUF domain is important for expression of constructs as soluble proteins in E. coli and that inclusion of the K1 domain in chimeric variants should be avoided, if possible.
[0429] Furthermore, based on periodontal bone loss and epitope analysis data from animal studies, the K1 domain may not significantly enhance protection, especially in the absence of a protective antigen that generates antisera that binds to the K1 epitope ABM5. Therefore, omitting the K1 (or K1n) domain improves solubility without significantly affecting vaccine efficacy.
[0430] Examination of antibody responses to different segments of the chimera (K, D, A, and K1) and suspected important epitopes (KAS, ABM2, ABM3, EP1) using protective and non-protective sera did not provide any clear pattern, although it was clear that these protected chimeric variants tended to show strong (IgG / IgG1) responses to intact P. gingivalis cells and against known protective epitopes (KAS, DUF, ABM), thus appearing that protection may not be related to any one epitope but more to the combination of epitopes required to ensure adequate protection against periodontal bone loss.
Claims
1. A chimeric or fusion protein for inducing an immune response to Porphyromonas gingivalis (P. gingivalis), the protein comprising a first polypeptide and a second polypeptide, wherein: A) the first polypeptide comprises or consists of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto; and B) the second polypeptide comprises or consists of the amino acid sequence of the adhesin domain of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis; wherein the second polypeptide comprises one or more adhesin binding motif (ABM) sequences, And among them: a) the second polypeptide does not include: the sequence of a cleaved adhesin domain (CAD); and / or b) the second polypeptide comprises an amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain, or a sequence that is at least 80% identical thereto.
2. The chimeric or fusion protein of claim 1, wherein the one or more ABMs comprise a sequence as shown in SEQ ID NO: 15 or 21, SEQ ID NO: 14 or 20 and / or SEQ ID NO: 17 or 22, or a sequence at least 80% identical thereto.
3. The chimeric or fusion protein of claim 1 or 2, wherein the one or more ABMs comprise the sequence set forth in SEQ ID NO: 16 or any one of SEQ ID NOs: 18, 19, or 23, or a sequence at least 80% identical thereto.
4. The chimeric or fusion protein according to any one of claims 1 to 3, wherein the chimeric or fusion protein does not comprise a sequence of CAD or a portion thereof having the amino acid sequence shown in SEQ ID NO: 12 or 13 or a sequence at least 80% identical thereto.
5. The chimeric or fusion protein of any one of claims 1 to 4, wherein the amino acid sequence substantially corresponding to the full length of the DUF2436 domain of Arg-gingipain or Lys-gingipain is a sequence that accounts for at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the length of the DUF2436 domain of Arg-gingipain or Lys-gingipain.
6. The chimeric or fusion protein of claim 5, wherein the amino acid sequence of the DUF2436 domain of Arg-gingipain or Lys-gingipain is the sequence set forth in SEQ ID NO: 24, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
7. The chimeric or fusion protein of any one of claims 1 to 6, wherein the second polypeptide comprises the sequence set forth in any one of SEQ ID NOs: 26, 27, 28, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
8. The chimeric or fusion protein of any one of claims 1 to 7, wherein the first polypeptide is linked to the second polypeptide.
9. The chimeric or fusion protein of any one of claims 1 to 8, wherein the first polypeptide is located at the N-terminus of the second polypeptide.
10. The chimeric or fusion protein of any one of claims 1 to 9, wherein the first polypeptide is directly conjugated to the second polypeptide.
11. The chimeric or fusion protein of any one of claims 1 to 9, wherein the first polypeptide is connected to the second polypeptide via a linker.
12. The chimeric or fusion protein of claim 11, wherein the linker is a peptide linker.
13. The chimeric or fusion protein of claim 12, wherein the peptide linker comprises at least 2 amino acids, at least 5 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, preferably wherein the linker comprises no more than 50 amino acids.
14. The chimeric or fusion protein of claim 12 or 13, wherein the peptide linker is no more than 25 amino acids, no more than 20 amino acids, no more than 15 amino acids, or no more than 10 amino acids.
15. The chimeric or fusion protein of any one of claims 1 to 14, wherein the first polypeptide comprises or consists of an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 11, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
16. The chimeric or fusion protein of claim 15, wherein the first polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1 or 2, or a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
17. The chimeric or fusion protein of any one of claims 1 to 16, wherein the chimeric or fusion protein comprises one or more additional polypeptides comprising or consisting of the amino acid sequence of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis or a sequence that is at least 80% identical thereto.
18. The chimeric or fusion protein of claim 17, wherein the one or more additional polypeptides comprising or consisting of the active site of Arg-gingipain or Lys-gingipain of Porphyromonas gingivalis are located at the N-terminus of the first polypeptide, the C-terminus of the first polypeptide, the N-terminus of the second polypeptide, or the C-terminus of the second polypeptide.
19. The chimeric or fusion protein of claim 18, wherein the one or more additional polypeptides are directly linked to the first polypeptide or the second polypeptide of the chimeric or fusion protein.
20. The chimeric or fusion protein of claim 19, wherein the one or more additional polypeptides are linked to the first polypeptide or the second polypeptide via a peptide linker.
21. The chimeric or fusion protein of claim 20, wherein the peptide linker comprises at least 2 amino acids, at least 5 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, preferably wherein the linker comprises no more than 50 amino acids.
22. The chimeric or fusion protein of claim 20 or 21, wherein the peptide linker is no more than 25 amino acids, no more than 20 amino acids, no more than 15 amino acids, or no more than 10 amino acids.
23. The chimeric or fusion protein according to any one of claims 17 to 22, wherein the one or more additional polypeptides preferably comprise or consist of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 1 to 11, or a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
24. The chimeric or fusion protein of claim 22, wherein the first polypeptide and the one or more additional polypeptides are identical or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each other.
25. The chimeric or fusion protein of claim 23, wherein the first polypeptide and the one or more additional polypeptides comprise the amino acid sequence of the active site of a heterologous gingipain from Porphyromonas gingivalis.
26. The chimeric or fusion protein of claim 23, wherein the first polypeptide and the one or more additional polypeptides comprise the amino acid sequence of the active site of Lys-gingipain.
27. The chimeric or fusion protein of claim 23, wherein the first polypeptide comprises the amino acid sequence of the active site of Lys-gingipain and the one or more additional polypeptides comprise the amino acid sequence of the active site of Arg-gingipain.
28. The chimeric or fusion protein of any one of claims 1 to 27, wherein the chimeric or fusion protein comprises or consists of the amino acid sequence shown in any one of SEQ ID NO:, 29, 30, 31, 32, 33, 34, 41 or 42, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% thereof.
29. The chimeric or fusion protein of any one of claims 1 to 28, wherein the protein comprises additional amino acid residues to facilitate expression in a recombinant expression system and / or to facilitate purification of the protein.
30. The chimeric or fusion protein of claim 29, wherein the additional amino acids comprise one, two, three, four or five amino acids in the N-terminal region, optionally including an N-terminal methionine and / or alanine residue.
31. The chimeric or fusion protein of claim 29 or 30, wherein the additional amino acids comprise one, two, three, four or five amino acids in the C-terminal region.
32. A nucleic acid encoding the chimeric or fusion protein of any one of claims 1 to 31.
33. A vector or construct comprising the nucleic acid of claim 32.
34. A host cell comprising the nucleic acid of claim 32 or the vector or construct of claim 33.
35. A composition comprising the chimeric or fusion protein of any one of claims 1 to 31.
36. The composition of claim 35, wherein the composition is a vaccine composition and comprises one or more adjuvants for enhancing the immune response to the chimeric or fusion protein.
37. A vaccine or immunostimulatory composition comprising the chimeric or fusion protein according to any one of claims 1 to 31 and optionally an adjuvant for enhancing the immune response to the chimeric or fusion protein.
38. A method for inducing an immune response to Porphyromonas gingivalis in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein according to any one of claims 1 to 31, a composition according to claim 35 or 36, or a vaccine or immunostimulatory composition according to claim 37.
39. A method of inducing a humoral immune response to Porphyromonas gingivalis in a subject, the method comprising administering to the subject a chimeric or fusion protein according to any one of claims 1 to 31, a composition according to claim 35 or 36, or a vaccine or immunostimulatory composition according to claim 37.
40. The method of claim 39, wherein the induced immune response comprises a switch from a Th1 to a Th2 immune response.
41. A method of immunizing a subject against infection by Porphyromonas gingivalis, the method comprising administering to the subject a chimeric or fusion protein according to any one of claims 1 to 31, a composition according to claim 35 or 36, or a vaccine or immunostimulatory composition according to claim 37.
42. A method of treating a Porphyromonas gingivalis infection in a subject, the method comprising administering to a subject in need thereof a chimeric or fusion protein according to any one of claims 1 to 31, a composition according to claim 35 or 36, or a vaccine or immunostimulatory composition according to claim 37.
43. A method for reducing or minimizing the severity of symptoms associated with Porphyromonas gingivalis infection, the method comprising administering to an individual in need thereof a chimeric or fusion protein according to any one of claims 1 to 31, a composition according to claim 35 or 36, or a vaccine or immunostimulatory composition according to claim 378, wherein the symptom is selected from the group consisting of swollen or puffy gums, gums that bleed easily, receding gums, periodontal pockets around the teeth, loss of tissue supporting the teeth (periodontal ligament, cementum and / or alveolar bone), pus between the gums and teeth, and gingivitis.
44. The method of claim 42 or 34, wherein the method further comprises administering one or more of: an antimicrobial compound, an anti-inflammatory agent.
45. Use of a chimeric or fusion protein according to any one of claims 1 to 31 for the preparation of a medicament for: Inducing an immune response to Porphyromonas gingivalis in a subject; ●Immunize subjects against Porphyromonas gingivalis infection; Treating the Porphyromonas gingivalis infection in the subject; or - Minimizing or reducing the severity of one or more symptoms of a Porphyromonas gingivalis infection.
46. The chimeric or fusion protein of any one of claims 1 to 31, the composition of claim 35 or 36, or the vaccine or immunostimulatory composition of claim 37, for use in: Inducing an immune response to Porphyromonas gingivalis in a subject; ●Immunize subjects against Porphyromonas gingivalis infection; Treating the Porphyromonas gingivalis infection in the subject; or - Minimizing or reducing the severity of one or more symptoms of a Porphyromonas gingivalis infection.
47. A method for obtaining antibodies against Porphyromonas gingivalis, the method comprising administering to a non-human animal a chimeric or fusion protein according to any one of claims 1 to 31, a composition according to claim 35 or 36, or a vaccine or immunostimulatory composition according to claim 37, thereby producing antibodies against Porphyromonas gingivalis in the animal.
48. The method of claim 47, wherein the method further comprises isolating the antibody from the animal or an egg of the animal.
49. An antibody preparation comprising antibodies against Porphyromonas gingivalis, wherein the antibody preparation is obtained by administering a chimeric or fusion protein according to any one of claims 1 to 31, a composition according to claim 35 or 36, or a vaccine or immunostimulatory composition according to claim 37 to a non-human animal, thereby producing antibodies against Porphyromonas gingivalis in the animal, and isolating the antibodies from the animal or its eggs.
50. A kit comprising a composition comprising the chimeric or fusion protein of any one of claims 1 to 31, the composition of claim 35 or 26, or the vaccine or immunostimulatory composition of claim 37, wherein optionally the kit comprises one or more cytokines and / or adjuvants in a sealed container, preferably wherein the kit comprises a label or package insert indicating that the composition is for immunizing an individual, optionally wherein the label or package insert comprises instructions for use.
